ziprasidone profile

Ziprasidone is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. It is a dopamine and serotonin antagonist, meaning it blocks the action of these neurotransmitters in the brain. Ziprasidone is thought to work by reducing the activity of dopamine and serotonin in the mesolimbic pathway, which is thought to be involved in the symptoms of schizophrenia. It is also thought to work by increasing the activity of serotonin in the prefrontal cortex, which is thought to be involved in cognitive function. Ziprasidone was first synthesized in the 1980s and was approved for use in the United States in 2001. It is typically taken orally, either as a tablet or as a suspension. Common side effects of ziprasidone include drowsiness, dizziness, weight gain, and constipation. More serious side effects can include movement disorders, such as tardive dyskinesia, and a potentially life-threatening condition called neuroleptic malignant syndrome. Ziprasidone is studied extensively because it is a relatively new antipsychotic that has been shown to be effective in treating both positive and negative symptoms of schizophrenia. It is also being studied for its potential to treat other mental health conditions, such as bipolar disorder, major depressive disorder, and anxiety disorders.'

ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	60854
CHEMBL ID	708
CHEBI ID	10119
SCHEMBL ID	28028
MeSH ID	M0243639

Synonym
BIDD:GT0042
5-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one
5-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one (ziprasidone)
5-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one(norastemizole)
bdbm50048803
5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one
gtpl59
5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one
ziprasidone [inn:ban]
ziprazidone
2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-
ziprasidonum
ziprasidona
CHEBI:10119 ,
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one
C07568 ,
146939-27-7
ziprasidone
MLS000759435
smr000466328
DB00246
5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
zipradon
CHEMBL708 ,
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
L000659
D08687
zipradon (tn)
ziprasidone (inn)
FT-0654208
FT-0655916
5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride monohydrate
A808568
cp88059;5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-indolin-2-one
A807468
6uka5vej6x ,
unii-6uka5vej6x
hsdb 7745
tox21_112194
tox21_113525
cas-146939-27-7
dtxsid4023753 ,
dtxcid403753
VU0286234-2
HY-14542
CS-1071
NCGC00263539-03
ziprasidone [mart.]
ziprasidone [inn]
ziprasidone [vandf]
ziprasidone [who-dd]
ziprasidone [hsdb]
ziprasidone [mi]
AKOS015900383
AB00639925-04
AB00639925-02
2h-indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-
AM90310
SCHEMBL28028
NCGC00263539-01
tox21_112194_1
5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one
MVWVFYHBGMAFLY-UHFFFAOYSA-N
5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one
AC-23360
Z0034
AB00639925_05
AB00639925_06
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1h-indol-2-one
5-(2-(4-(1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chlorooxindole
NCGC00263539-05
Q205517
SDCCGSBI-0633778.P001
NCGC00263539-13
HMS3742M19
D92803
ziprasidone- bio-x
BZ164575
BVB74558
EN300-7415908
n05ae04
ziprasidone (mart.)
6-chloro-5-
5-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
ziprasidone, 1mg/ml in 1,2-dimethoxyethane

Excerpt	Reference	Relevance
"Ziprasidone hydrochloride is a second-generation antipsychotic drug employed for the treatment of schizophrenia and acute mania or mixed episodes associated with bipolar disorder. "	( Identification of Novel Impurity of Ziprasidone. Bhat, K; Godbole, HM; Murkute, SR; Singh, GP; Trivedi, A; Upadhyay, PR; Vasantharaju, SG, 2022)	2.44
"Ziprasidone (ZP) is a novel atypical antipsychotic agent effective in the treatment of positive and negative symptoms of schizophrenia with low chances for extrapyramidal side effects (EPs) and cognitive deficits. "	( Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy. Ahmad, FJ; Ahmed, MZ; Hasan, N; Jain, GK; Khan, UA; Parveen, U; Saad, S, 2020)	2.24
"Ziprasidone (ZIP) is an effective antipsychotic with low side effects than other second-generation antipsychotics. "	( The Influence of a Xanthine-Catechin Chemical Matrix on in vitro Macrophage-Activation Triggered by Antipsychotic Ziprasidone. Azzolin, VF; Barbisan, F; da Cruz Jung, IE; da Cruz, IBM; da Cunha, BSN; do Prado-Lima, PA; Duarte, MMMF; Duarte, T; Ribeiro, EE; Turra, BO, 2019)	2.17
"Ziprasidone is an atypical antipsychotic recommended to be administered twice daily."	( Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. Borlido, C; Caravaggio, F; Deluca, V; Graff-Guerrero, A; Ismail, Z; Mamo, D; Mulsant, B; Pollock, B; Remington, G; Suzuki, T; Uchida, H, 2013)	2.13
"Ziprasidone is a second-generation antipsychotic with a lower propensity to cause extrapyramidal adverse effects that are seen at higher doses. "	( Acute dystonia, akathisia, and parkinsonism induced by ziprasidone. Jana, AK; Praharaj, SK; Sarkhel, S; Sinha, VK, )	1.82
"Ziprasidone appears to be a good switching option for patients with bipolar I disorder experiencing suboptimal response or intolerance with olanzapine in combination with lithium or valproate. "	( The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study. Bahk, WM; Kim, MD; Kwon, YJ; Lee, HB; Lee, JG; Woo, YS; Yoon, BH, 2013)	2.1
"Ziprasidone is a second-generation antipsychotic (SGA) approved for agitation. "	( Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting. Feifel, D; MacDonald, K; Ronquillo, L; Vilke, GM; Wilson, MP, 2013)	2.19
"Ziprasidone is an atypical antipsychotic that can also cause dangerous interactions to cause SS because it is not only a potent 5-HT1A agonist but also has been reported to inhibit serotonin reuptake with an affinity similar to tricyclic antidepressants, in addition to inhibiting reuptake of norepinephrine."	( Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. Assaly, R; El-Okdi, NS; Ghose, A; Karanovic, D; Lumbrezer, D, )	1.11
"Ziprasidone is a benzisothiazolyl piperazine derivative that was developed from the chemically related antipsychotic drug tiospirone, and it improves neurological functions of the ischemic brain and is effective in treatment of schizophrenia. "	( Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats. Baek, SE; Do, BR; Kaengkan, P; Kam, KY; Kang, SG; Kim, JY; Lee, ES, 2013)	2.09
"Ziprasidone is a poorly water-soluble antipsychotic drug that demonstrates low fasted state oral bioavailability and a clinically significant two-fold increase in absorption when dosed postprandially. "	( Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro. Dening, TJ; Prestidge, CA; Rao, S; Thomas, N, 2016)	2.1
"Ziprasidone is a SGA that is efficacious in the treatment of schizophrenia."	( Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. Choi, SM; Kim, NR; Kim, YH; Lee, CH; Lee, JG; Lee, SJ; Park, SW, 2009)	1.38
"Ziprasidone is an atypical antipsychotic drug that was approved by the Food and Drug Administration in February 2001 for the general treatment of schizophrenia in adults."	( Pediatric ziprasidone overdose. Fasano, CJ; Lares, C; O'Malley, GF; Rowden, AK, 2009)	1.48
"Ziprasidone is a newer "atypical" or "second-generation" antipsychotic. "	( Using oral ziprasidone effectively: the food effect and dose-response. Citrome, L, 2009)	2.19
"Ziprasidone is an effective, safe, and well-tolerated adjunctive treatment with a mood stabilizer for long-term maintenance treatment of bipolar mania."	( Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. Bowden, CL; Ice, KS; Schwartz, JH; Versavel, M; Vieta, E; Wang, PP, 2010)	3.25
"Ziprasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar mania in adults and is used off label in children and adolescents. "	( Respiratory failure following isolated ziprasidone ingestion in a toddler. Gresham, C; Ruha, AM, 2010)	2.07
"Ziprasidone is an 'atypical' or 'second-generation' antipsychotic that has garnered clinical interest because of its metabolically friendly tolerability profile."	( Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. Citrome, L, 2010)	2.52
"Ziprasidone is a psychotropic agent used for the treatment of schizophrenia. "	( Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes. Gumustas, M; Kul, D; Ozkan, SA; Uslu, B, 2010)	2.05
"Ziprasidone is a second-generation antipsychotic approved for the treatment of schizophrenia and bipolar disorder. "	( Drug safety evaluation of ziprasidone. Citrome, L, 2011)	2.11
"Ziprasidone is an atypical antipsychotic with affinity to the D2, 5HT2A, 5HT2C, 5HT1A, 5HT1B/1D receptors. "	( [Practical aspects of the use of ziprasidone in schizophrenia]. Jarema, M; Ochedzan, D, )	1.86
"Ziprasidone (ZPN) is an atypical antipsychotic drug used mainly for the treatment of schizophrenia."	( Cytogenetic effects of valproic acid and ziprasidone in human lymphocyte cultures. Akritopoulou, K; Anestakis, D; Ekonomopoulou, MT; Iakovidou-Kritsi, Z; Karapidaki, I, 2011)	1.36
"Ziprasidone is an atypical antipsychotic drug used for the treatment of schizophrenia. "	( Ziprasidone attenuates brain injury after focal cerebral ischemia induced by middle cerebral artery occlusion in rats. Choi, YW; Jalin, AM; Kaengkan, P; Kam, KY; Kang, SG; Kim, YH; Park, SW, 2012)	3.26
"Ziprasidone is a novel antipsychotic agent with a pharmacological profile distinct from that of other currently available novel or classical antipsychotics. "	( Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. Gunasekara, NS; Keating, GM; Spencer, CM, 2002)	2.13
"Ziprasidone is a promising new antipsychotic that has shown significant efficacy in the oral treatment of patients with schizophrenia or schizoaffective disorder. "	( Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. Gunasekara, NS; Keating, GM; Spencer, CM, 2002)	2.13
"Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. "	( Brief report on Ziprasidone. Chowdhury, WA; Firoz, AH; Mamun, AA; Rahman, AH, 2002)	2.1
"Ziprasidone is an atypical antipsychotic recently approved by the Food and Drug Administration for the treatment of psychosis."	( Ziprasidone-associated mania: a case series and review of the mechanism. Baldassano, CF; Ballas, C; Datto, SM; Kim, D; Littman, L; O'Reardon, J; Rynn, MA, 2003)	2.48
"Ziprasidone is a new atypical antipsychotic recently marketed in a number of countries. "	( Ziprasidone in the management of schizophrenia : the QT interval issue in context. Taylor, D, 2003)	3.2
"Ziprasidone is an atypical antipsychotic with a high ratio of 5-HT(2A) to D(2) receptor antagonism. "	( Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. Gilbert, DL; Miceli, JJ; Robarge, L; Sallee, FR; Vinks, AA; Wilner, K, 2003)	2.09
"Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT(2) receptors compared with dopamine D(2) receptors in vitro. "	( A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Kapur, S; Mamo, D; Mann, S; Papatheodorou, G; Remington, G; Shammi, CM; Therrien, F, 2004)	1.97
"Ziprasidone is an atypical antipsychotic that is approved for the treatment of adults with schizophrenia. "	( Ziprasidone treatment of two adolescents with psychosis. McDougle, CJ; Meighen, KG; Shelton, HM, 2004)	3.21
"Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD). "	( Tardive dyskinesia in 2 patients treated with ziprasidone. Ananth, J; Burgoyne, KS; Niz, D; Smith, M, 2004)	2.02
"Ziprasidone (Geodon) is a relatively new atypical antipsychotic medication with a unique pharmacological profile. "	( Ziprasidone: a novel psychotropic with unique properties. Baldassano, C; Ballas, C; Ballas, P; O'Reardon, J; Yang, C, 2004)	3.21
"Ziprasidone is an atypical antipsychotic with a highly specific receptorbinding profile that has been shown to be effective for both positive and negative symptoms of schizophrenia. "	( Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. Ayani, I; Bernardo, M; Florez, Td; Gandía, R; Gómez-Criado, MS; Gutiérrez, JR, 2005)	3.21
"Ziprasidone is a neuroleptic drug recently sold in Spain. "	( Ziprasidone overdose: cardiac safety. Gutiérrez Casares, JR; Insa Gómez, FJ, )	3.02
"Ziprasidone is a second-generation antipsychotic that received Food and Drug Administration approval in February 2001. "	( From clinical research to clinical practice: a 4-year review of ziprasidone. Daniel, DG; Harvey, PD; Kilts, CD; Lieberman, JA; Nemeroff, CB; Newcomer, JW; Schatzberg, AF; Weiden, PJ, 2005)	2.01
"Ziprasidone is a new atypical antipsychotic with reported low potential for extrapyramidal side effects."	( Acute dystonia after initial doses of ziprasidone: a case report. Savas, E; Savas, HA; Selek, S; Yumru, M, 2006)	1.33
"Ziprasidone is an effective treatment for hostility in patients with schizophrenia or schizoaffective disorder."	( Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J, 2006)	2.16
"Ziprasidone is a second-generation antipsychotic currently marketed for the treatment of schizophrenia and bipolar mania. "	( Ziprasidone in bipolar disorder. Versiani, M, 2006)	3.22
"Ziprasidone is a valid and effective choice amongst antipsychotic medications, but this case calls for caution regarding ACRs at the time of prescribing."	( Urticaria and angio-oedema due to ziprasidone. Akkaya, C; Aydogan, K; Kirli, S; Sarandol, A, 2007)	1.34
"Ziprasidone is a newer "atypical" or "second-generation" antipsychotic. "	( Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. Citrome, L; Greenberg, WM, 2007)	3.23
"Ziprasidone is an atypical antipsychotic associated with QTc prolongation during therapeutic use. "	( Prospective observational multi-poison center study of ziprasidone exposures. Benson, BE; Crouch, BI; Klein-Schwartz, W; Lofton, AL; Spiller, HA, )	1.82
"Ziprasidone (CP-88,059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects in preclinical assays predictive of antipsychotic activity. "	( Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Guanowsky, V; Howard, HR; Lebel, LA; Lowe, JA; McLean, S; Schmidt, AW; Schulz, DW; Seeger, TF; Seymour, PA; Zorn, SH, 1995)	3.18
"Ziprasidone is a novel antipsychotic agent, with high affinity for dopamine D2 and serotonin (5-HT2) receptors in vitro and in animal models. "	( Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. Alpert, NM; Babich, JW; Bonab, AA; Elmaleh, DR; Fischman, AJ; Rauch, SL; Rubin, RH; Shoup, TM; Williams, SA, 1996)	1.93
"Ziprasidone is an antipsychotic agent indicated primarily for the treatment of schizophrenia. "	( Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. Blake, JF; Chrunyk, B; Duffy, EM; Kim, Y; Massefski, W; Oksanen, DA, 1998)	2.04
"Ziprasidone is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites. "	( Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Braselton, JP; Reynolds, LS; Rollema, H; Sprouse, JS; Zorn, SH, 1999)	2.02
"Ziprasidone (Zeldox) is a novel antipsychotic with a unique combination of antagonist activities at monoaminergic receptors and transporters and potent agonist activity at serotonin 5-HT(1A) receptors. "	( 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Lu, Y; Rollema, H; Schmidt, AW; Sprouse, JS; Zorn, SH, 2000)	2.01
"Ziprasidone is a novel antipsychotic agent with a unique combination of pharmacological activities at human receptors. "	( Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Howard, HR; Lebel, LA; Schmidt, AW; Zorn, SH, 2001)	3.2
"Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. "	( Focus on ziprasidone. Green, B, 2001)	2.17
"Ziprasidone is a benzisothiazolyl piperazine-type atypical antipsychotic that shares the serotonin(2A)/dopamine(2) (5-HT(2A)/D(2)) profile of the available atypical antipsychotics. "	( Ziprasidone: the fifth atypical antipsychotic. Caley, CF; Cooper, CK, 2002)	3.2
"Ziprasidone is a safe and efficacious atypical antipsychotic for the acute management of schizophrenia. "	( Ziprasidone: the fifth atypical antipsychotic. Caley, CF; Cooper, CK, 2002)	3.2
"Ziprasidone is a novel antipsychotic agent with a pharmacological profile distinct from that of other currently available novel or classical antipsychotics. "	( Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Gunasekara, NS; Keating, GM; Spencer, CM, 2002)	3.2
"Ziprasidone is a promising new antipsychotic that has shown significant efficacy in the oral treatment of patients with schizophrenia or schizoaffective disorder. "	( Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Gunasekara, NS; Keating, GM; Spencer, CM, 2002)	3.2
"Ziprasidone is a novel antipsychotic with a unique pharmacologic profile. "	( A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A, 2002)	2.06

Excerpt	Reference	Relevance
"Ziprasidone has a generally favourable adverse effect profile."	( Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. Ice, K; Loebel, A; Lombardo, I; Warrington, L, 2007)	2.5
"Ziprasidone has less glucose and lipid metabolic effect for first-episode schizophrenia patients in short-term treatment. "	( [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia]. Chen, H; Fang, M; Ou, J; Shao, P; Wu, R; Xu, Y; Zhao, J, 2013)	2.21
"Ziprasidone has been reported efficacious in this population but the evidence is limited."	( Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. Conrad, SA; Green, R; McCarthy, PJ; Scott, LK, 2009)	1.29
"Ziprasidone has similar efficacy and safety in black patients with schizophrenia compared with patients in the white and overall populations."	( Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M, 2009)	3.24
"Ziprasidone has been rarely associated with QT prolongation especially in patients (1) with no underlying cardiac or metabolic disorders, (2) who are receiving no concomitant medications known to prolong the QT interval, and (3) whom therapy is being initiated at a low dose. "	( Single-dose ziprasidone associated with QT interval prolongation. Mycyk, MB; Witsil, JC; Zell-Kanter, M, 2012)	2.2
"Ziprasidone has been associated with prolonged QTc Intervals."	( Continuum of care: stabilizing the acutely agitated patient. Bellnier, TJ, 2002)	1.04
"Ziprasidone has relatively fewer side effects and yet has at least equivalent efficacy for florid 'positive' symptoms compared to conventional anti psychotics."	( Brief report on Ziprasidone. Chowdhury, WA; Firoz, AH; Mamun, AA; Rahman, AH, 2002)	1.38
"As ziprasidone has substantial serotonergic and noradrenergic action, we hypothesize, it may more likely induce mania than other atypical antipsychotics."	( Ziprasidone-associated mania: a case series and review of the mechanism. Baldassano, CF; Ballas, C; Datto, SM; Kim, D; Littman, L; O'Reardon, J; Rynn, MA, 2003)	2.28
"Ziprasidone has moderate affinity for serotonin and norepinephrine reuptake sites, predicting antidepressant/anxiolytic activity."	( The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Shayegan, DK; Stahl, SM, 2003)	1.34
"Ziprasidone has shown long-term antipsychotic efficacy in comparisons with haloperidol, olanzapine, and risperidone, as well as efficacy in patients switched from another antipsychotic agent."	( Maintaining symptom control: review of ziprasidone long-term efficacy data. Schooler, NR, 2003)	1.31
"Ziprasidone has been shown to be effective in the treatment of bipolar disorder in patients experiencing manic or mixed episodes."	( Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. Ice, K; Loebel, A; Lombardo, I; Warrington, L, 2007)	2.5
"Ziprasidone has been used to treat schizophrenia since 2000. "	( The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. D'Agostino, RB; Eng, SM; Faich, GA; Kane, JM; Reynolds, RF; Ruskin, JN; Strom, BL, 2008)	2.35
"Ziprasidone has been weight neutral in adult populations, but data from adolescents and patients with autism are sparse."	( Ziprasidone in adolescents with autism: an open-label pilot study. Cater, JR; Delaney, MA; Hyman, SB; Malone, RP, 2007)	2.5
"Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential."	( Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Guanowsky, V; Howard, HR; Lebel, LA; Lowe, JA; McLean, S; Schmidt, AW; Schulz, DW; Seeger, TF; Seymour, PA; Zorn, SH, 1995)	2.46
"Ziprasidone has high affinity for human 5-HT receptors and for human dopamine D(2) receptors."	( Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Howard, HR; Lebel, LA; Schmidt, AW; Zorn, SH, 2001)	2.47
"Ziprasidone has relatively fewer side-effects and yet has at least equivalent efficacy for florid 'positive' symptoms compared with conventional antipsychotics."	( Focus on ziprasidone. Green, B, 2001)	1.45
"Ziprasidone has been reported to be an effective antipsychotic drug for both positive and negative symptoms of schizophrenia, and long-term use has been effective in preventing relapse. "	( Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Gutierrez, MA; Lee, V; Stimmel, GL, 2002)	3.2
"Ziprasidone has demonstrated in vitro activity as a 5-HT(1A) receptor agonist and as a very weak inhibitor of serotonin and norepinephrine reuptake."	( Ziprasidone: the fifth atypical antipsychotic. Caley, CF; Cooper, CK, 2002)	2.48

Excerpt	Reference	Relevance
"Ziprasidone induces lower D2 RO and EPS than haloperidol, which is consistent with an atypical antipsychotic profile. "	( Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Aguilar, Y; Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Mena, E; Perez, V; Puigdemont, D, 2005)	1.98
"Ziprasidone did not increase body weight and was associated with a favorable metabolic profile during the continuation study period."	( Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study. Giller, E; Khanna, S; Loebel, AD; Potkin, SG; Rajadhyaksha, S; Siu, CO, 2007)	2.5

Excerpt	Reference	Relevance
"In ziprasidone-treated rats only decreased CAT activity was found."	( Effects of several atypical antipsychotics closapine, sertindole or ziprasidone on hepatic antioxidant enzymes: Possible role in drug-induced liver dysfunction. Blagojević, D; Brkljačić, J; Miler, M; Miljević, Č; Milošević, V; Nikolić, M; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Platanić Arizanović, L; Spasić, S; Tatalović, N; Vidonja Uzelac, T, 2021)	1.37
"Ziprasidone treatment was also associated with statistically significant improvements in the GAF, WHO-DAS-II, and SF-12."	( Switching to ziprasidone in the clinical practice setting: an open-label study. Bobes García, J; de la Gándara Martín, JJ; Gutiérrez Fraile, M, 2013)	1.48
"Ziprasidone treatment reduced both the rate of MetS and its individual risk factors in subjects with schizophrenia and related psychotic disorders. "	( The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. Chue, P; Mandel, FS; Therrien, F, 2014)	2.21
"Ziprasidone-treated patients had a significantly greater increase in global akathisia scores (P = .01) and significant weight increase (mean [SD] = 3.5 [11.8] kg, or 7.7 [26.1] lb) compared to placebo (1.0 [6.4] kg, or 2.2 [14.1] lb) (P = .03)."	( Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. Baer, L; Bobo, WV; Curren, L; Fava, M; Mischoulon, D; Papakostas, GI; Shelton, RC, 2017)	2.62
"Ziprasidone-treated patients lost an average of 2.1 kg in the 12 weeks of the study, the mean weight for risperidone and quetiapine remained unchanged, and patients receiving olanzapine gained 3.1 kg on average."	( Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. Haug, HJ; Kolb, SA; Koponen, H; Lublin, H; Sigmundsson, T, 2009)	2.52
"Ziprasidone-treated patients who completed the study showed greater improvement in depressive symptoms assessed by Montgomery and Asberg Depression Rating Scale than risperidone-treated patients (P < 0.05)."	( A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Addington, DE; Johnson, G; Kulkarni, J; Labelle, A; Loebel, A; Mandel, FS, 2009)	1.42
"Ziprasidone-treated patients also demonstrated significant improvements on the Mania Rating Scale and all secondary efficacy measures, and had significantly higher response and remission rates compared with placebo."	( Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. Loebel, A; Lombardo, I; Mandel, FS; Stahl, S, 2010)	1.46
"Ziprasidone treatment was indistinguishable from placebo in assessments of movement disorders and was not associated with weight gain or cardiovascular abnormalities."	( A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Arato, M; Meltzer, HY; O'Connor, R, 2002)	1.29
"Ziprasidone treatment was associated with a significant weight loss of 8.1 lb (3.6 kg) as well as a significant reduction in total cholesterol and triglycerides (p < or =.05). "	( Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, S; Fitzgerald, B; Khan, A; Khan, S; Okos, A, 2003)	2.01
"Ziprasidone pretreatment decreased lethality in this mouse model of severe cocaine intoxication."	( Ziprasidone pretreatment attenuates the lethal effects of cocaine in a mouse model. Cleveland, NJ; Dewitt, CD; Heard, K, 2005)	3.21
"All ziprasidone treated animals displayed a normal four-day oestrous cycle."	( Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Fell, MJ; Gibson, R; Marshall, KM; McDermott, E; Neill, JC; Sisodia, G, 2005)	1.05
"ziprasidone for the treatment of acute agitation."	( Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Francis, A; Kohen, I; Preval, H; Southard, R, 2005)	1.32
"ziprasidone treatment. There was one adverse event in a patient with untreated benign prostatic hypertrophy who developed urinary retention."	( Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. Barak, Y; Baruch, Y; Mazeh, D; Plopski, I, 2006)	1.42
"Ziprasidone treatment was associated with clinically and statistically significant improvement in mean YMRS scores (-10.8 +/- 8.4, p < 0.0001) and 57% had a CGI-I	( A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Aleardi, M; Biederman, J; Dougherty, M; Mick, E; Spencer, T; Wozniak, J, 2007)	1.32
"Ziprasidone-treated patients were not clinically different from placebo-treated patients on the Simpson-Angus Rating scale, Barnes Akathisia scale and AIMS assessments."	( Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Buffenstein, A; Feighner, J; Ferguson, J; Harrigan, EP; Jaffe, W; Keck, P; Morrissey, MR, 1998)	2.46
"Ziprasidone treatment appeared to have no significant effect on BMI or glucose level, perhaps due to the small number of subjects."	( The apparent effects of ziprasidone on plasma lipids and glucose. Fayek, M; Kingsbury, SJ; Simpson, GM; Trufasiu, D; Zada, J, 2001)	1.34
"Treatment with ziprasidone was superior for extrapyramidal symptoms."	( Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. Bogers, JPAM; Broekman, TG; de Haan, L; Moleman, P; Schulte, PFJ, 2018)	1.05
"Treatment with ziprasidone avoids relapse episodes at a reasonable cost, generating savings for the NHCS."	( Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Azanza, JR; Bernardo, M; Rejas, J; Rubio-Terrés, C, )	0.69

Excerpt	Reference	Relevance
" This combination of effects may be responsible for its low rate of general adverse events, low rate of persistent prolactin elevation, low incidence of weight gain, low liability for inducing movement disorders, low rate of syncope and induction of decreases in lipid profile."	( Ziprasidone: profile on safety. Goodnick, PJ, 2001)	1.75
"Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other."	( Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. McIntyre, RS, 2002)	0.31
" They have apparently safe cardiac safety profiles in both therapeutic and supra-therapeutic doses."	( Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. Biswas, AK; Mayes, KL; Morris-Kukoski, CL; Zabrocki, LA, 2003)	0.58
" They have apparently safe cardiac safety profiles in both therapeutic and supratherapeutic doses, but recently the Federal Drug Administration has issued a caution regarding ziprasidone use in combination with other drugs that are known to prolong the QTc interval."	( Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. Biswas, AK; Mayes, KL; Morris-Kukoski, CL; Zabrocki, LA, 2003)	0.77
" This is because of their efficacy in the treatment of several psychiatric disorders, ease of administration, and absence of the well-known extrapyramidal adverse effects long-attributed to the standard dopamine blocking anti-psychotic medications."	( Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. Bailey, RK, 2003)	0.32
" The aim of this paper is to review literature about newer antipsychotics, focusing on their advantages in terms of efficacy and side effect profiles when compared to classical and older atypical antipsychotics, and to evaluate the efficacy of the different new antipsychotics when compared to one another."	( New antipsychotics and schizophrenia: a review on efficacy and side effects. Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A, 2004)	0.32
"Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics."	( The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Citrome, L; Volavka, J, 2004)	0.32
" However, there are still significant adverse effects and toxicities with this class of medications."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
"Continued research to evaluate adverse effects and tolerability of atypical antipsychotics compared with first-generation antipsychotics and each other is reviewed."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
"While new atypical antipsychotic medications may have a safer therapeutic and overdose profile than first-generation antipsychotic medications, many adverse and toxic effects still need to be considered in therapeutic monitoring and overdose management."	( Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois, D, 2005)	0.33
" Adverse events were generally mild to moderate, and no subjects were discontinued from the study."	( Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. Miceli, JJ; Swan, SK; Tensfeldt, TG; Wilner, KD, 2005)	0.57
"Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites."	( An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Grossi, P; Kanter, Rd; Monaci, S; Monshouwer, M; Turlizzi, E; Vignati, L, 2005)	0.33
" No cardiovascular adverse event or significant increase of the QTc interval was observed."	( Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Domin, S; Kasper, S; Kudla, D; Lambert, M; Naber, D, 2007)	0.6
" Outcome measures were taken at baseline, 6, and 12 months, and included the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI-S) scale, the Global Assessment of Functioning Scale (GAF) scores, treatment-emergent adverse events, body weight, and drug attitude."	( Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Gibel, A; Ratner, Y; Ritsner, MS; Yorkov, V, 2007)	0.6
"6%), adverse events (11."	( Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Gibel, A; Ratner, Y; Ritsner, MS; Yorkov, V, 2007)	0.6
" Treatment-emergent adverse events occurring during the pivotal trials revealed statistically significant NNH versus placebo (or placebo equivalent) for aripiprazole for headache (NNH = 20, 95% CI = 11 to 170) and nausea (NNH = 17, 95% CI = 11 to 38), for ziprasidone in the treatment of headache (NNH = 15, 95% CI = 8 to 703), and for olanzapine in treatment-emergent hypotension (NNH = 50, 95% CI = 30 to 154)."	( Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Citrome, L, 2007)	0.81
" In this study, we determined if subacute administration of the atypical antipsychotic ziprasidone altered the toxic effects of cocaine in mice."	( Administration of ziprasidone for 10 days increases cocaine toxicity in mice. Heard, K; Krier, S; Zahniser, NR, 2008)	0.9
" Insomnia and somnolence were the only adverse events with an incidence >10% in pooled subjects."	( Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. Loebel, A; O'Gorman, CJ; Simpson, GM; Yang, R, 2008)	0.58
" Safety evaluations included adverse event monitoring, electrocardiography, and standard laboratory assessments."	( Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. Horne, RL; Keck, PE; Loebel, AD; Versiani, M; Warrington, L, 2009)	0.63
"Almost all adverse events (98%) were mild to moderate in severity."	( Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. Horne, RL; Keck, PE; Loebel, AD; Versiani, M; Warrington, L, 2009)	0.63
" Treatment with antipsychotics in this limited pilot trial did not improve the number of days alive without delirium or coma, nor did it increase adverse outcomes."	( Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Bernard, GR; Canonico, AE; Carson, SS; Dittus, RS; Ely, EW; Girard, TD; Meltzer, HY; Pandharipande, PP; Pun, BT; Schmidt, GA; Shintani, AK; Thompson, JL; Wright, PE, 2010)	0.36
" Ziprasidone, a combined serotonin and dopamine receptor antagonist, is a second-generation antipsychotic agent with a lower incidence of extrapyramidal motor symptoms and prolactin elevation and a safer profile of adverse effects on plasma lipids, glucose levels, and body weight than other antipsychotics."	( Safety of the electroconvulsive therapy-ziprasidone combination. Florakis, A; Markatou, M; Masdrakis, VG; Oulis, P; Tzanoulinos, G, 2010)	1.54
"5, and 5mg/kg/day) administration caused no observable adverse effects."	( Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Harada, K; Irie, M; Kayama, Y; Kondo, Y; Matsuoka, N; Mihara, T; Ni, K; Shobo, M; Yamada, H, 2011)	0.57
" Safety measures included adverse event (AE) reporting and administration of the Abnormal Involuntary Movement Scale (AIMS)."	( Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. Bachinsky, M; Cavus, I; Chappell, P; Glue, P; Karayal, ON; Kolluri, S; Stewart, M, 2011)	0.66
"7%); the proportion who discontinued due to adverse events was similar (10."	( Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Cucchiaro, J; Loebel, A; Ogasa, M; Potkin, SG, 2011)	0.6
" To assess safety, we measured drug-related adverse events, weight, lipid variables, prolactin, and corrected QT (QTc) interval."	( Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. Chung, YC; Huang, GB; Kim, MG; Lee, KH; Park, TW; Yang, JC; Zhao, T, 2012)	0.69
"Ziprasidone appeared well tolerated; most adverse events were of mild or moderate severity."	( Long-term safety of ziprasidone in schizophrenic patients: an open trial. Piazzi, G; Sciarretta, A, 2012)	2.15
" Treatment-emergent adverse events (TEAEs), most mild to moderate in severity, included headache (13."	( Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. Cutler, AJ; Kalali, AH; Kunovac, J; Mattingly, GW; Meng, X, 2013)	0.39
"This study aimed to examine the risk difference (RD) in the discontinuation due to adverse events, akathisia, overall extrapyramidal symptoms (EPS), reported-somnolence, and 7% or greater weight gain between ziprasidone monotherapy and placebo in the acute treatment of bipolar depression (BPD), bipolar mania (BPM), and schizophrenia."	( Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. Calabrese, JR; Gao, K; Karayal, ON; Kolluri, S; Pappadopulos, E, 2013)	0.81
"The RD in discontinuation due to adverse events or 7% or greater weight gain between ziprasidone and placebo was not significant in all 3 psychiatric conditions."	( Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. Calabrese, JR; Gao, K; Karayal, ON; Kolluri, S; Pappadopulos, E, 2013)	0.85
"Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups."	( Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. Calabrese, JR; Gao, K; Karayal, ON; Kolluri, S; Pappadopulos, E, 2013)	2.07
" Safety assessments included weight and body mass index (BMI), adverse events (AEs), vital signs, laboratory measures, electrocardiograms, and movement disorder ratings."	( Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. Cavuş, I; DelBello, MP; Findling, RL; Gundapaneni, BK; Pappadopulos, E; Schwartz, JH; Vanderburg, DG, 2013)	0.65
"The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in paranoid schizophrenia patients."	( Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Beszlej, A; Bienkowski, P; Frydecka, D; Grzywacz, A; Mierzejewski, P; Samochowiec, A; Samochowiec, J; Trześniowska-Drukała, B; Tybura, P, 2014)	0.63
"The reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 1997 to 2011 were reviewed to assess serious adverse events induced by the administration of antipsychotics to children."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
" Signals in the data that signified a drug-associated adverse event were detected via quantitative data mining algorithms."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
" Significant signals of the QT prolongation adverse event were detected only for ziprasidone and risperidone."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.64
"It was suggested that there is a level of diversity in the strength of the association between various first- and second-generation antipsychotics with associated serious adverse events, which possibly lead to fatal outcomes."	( Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T, 2015)	0.42
"While antipsychotic-induced extrapyramidal symptoms (EPS) and akathisia remain important concerns in the treatment of patients with schizophrenia, the relationship between movement disorder rating scales and spontaneously reported EPS-related adverse events (EPS-AEs) remains unexplored."	( Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales. Fleischhacker, WW; Karayal, ON; Kemmler, G; Kolluri, S; Vanderburg, D; Widschwendter, CG, 2015)	0.42
" EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale."	( Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015)	0.42
"Sexual dysfunction, as a noticeable adverse effect of atypical antipsychotic drugs (APDs) for the treatment of schizophrenia, has not been investigated in detail."	( Antipsychotic Drug-Mediated Adverse Effects on Rat Testicles May Be Caused by Altered Redox and Hormonal Homeostasis. Blagojević, D; Brkljačić, J; Mijović, M; Mijušković, A; Miljević, Č; Nestorović, V; Nikolić, M; Nikolić-Kokić, A; Oreščanin-Dušić, Z; Spasić, S; Tatalović, N; Vidonja Uzelac, T, 2022)	0.72
" Lastly, adverse events were recorded during treatment."	( The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study. Bai, L; Guo, Y; Li, J; Li, K; Li, Y; Liang, W; Liu, L; Liu, Z; Wang, J; Wang, X; Wu, Y; Xu, J; Yang, F; Yu, J; Zhang, C; Zhang, Y, 2023)	1.16
" In this study, 62 adverse events were reported."	( The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study. Bai, L; Guo, Y; Li, J; Li, K; Li, Y; Liang, W; Liu, L; Liu, Z; Wang, J; Wang, X; Wu, Y; Xu, J; Yang, F; Yu, J; Zhang, C; Zhang, Y, 2023)	1.16

Excerpt	Reference	Relevance
" Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0."	( The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Allard, S; Hamelin, BA; Laplante, L; LeBel, M; Miceli, J; Tremblay, J; Wilner, KD, )	1.25
" The drug's longer half-life under fasting conditions may reflect dissolution-limited absorption, although this could not be directly assessed."	( The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Allard, S; Hamelin, BA; Laplante, L; LeBel, M; Miceli, J; Tremblay, J; Wilner, KD, )	0.34
" Mean Cmax and AUC(0,12 h) increased with increasing dose, with apparent dose-proportionality between the 20 and 60 mg dose levels."	( Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Apseloff, G; Gerber, N; Hansen, RA; Johnson, AC; Miceli, JJ; Wilner, KD, 2000)	0.57
"Ziprasidone is characterized by a predictable pharmacokinetic profile resulting in symptoms that reflect its pharmacological action."	( Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Apseloff, G; Gerber, N; Hansen, RA; Johnson, AC; Miceli, JJ; Wilner, KD, 2000)	2.01
" The resulting data were used to derive pharmacokinetic parameters of ziprasidone in each age and gender group."	( Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Baris, B; Colburn, WA; Hansen, RA; Smolarek, TA; Tensfeldt, TG; Turncliff, RZ; Wilner, KD, 2000)	0.8
" Assessment of gender effects by analysis of variance revealed statistically significant differences in Cmax (85 vs."	( Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Baris, B; Colburn, WA; Hansen, RA; Smolarek, TA; Tensfeldt, TG; Turncliff, RZ; Wilner, KD, 2000)	0.57
" On day 5 there were no statistically significant differences in the Cmax or tmax for ziprasidone between the two groups."	( The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Anderson, KE; Anziano, RJ; Bauer, LA; Carithens, RL; Everson, G; Johnson, A; Lasseter, KC; Smolarek, TA; Turncliff, RZ; Wilner, KD, 2000)	0.84
" Pharmacokinetic variables were determined from multiple venous blood samples collected on days 1 and 8 (haemodialysis day for subjects with severe renal impairment)."	( The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Anziano, RJ; Aweeka, F; Horton, M; Jayesekara, D; Lambrecht, L; Sherwood, J; Smolarek, TA; Swan, S; Turncliff, RZ; Wilner, KD, 2000)	0.61
" These were assayed for ethinyloestradiol and levonorgestrel and the resulting data used to derive pharmacokinetic data for these steroids."	( Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000)	1.75
"The mean AUC(0,24 h), Cmax and tmax for ethinyloestradiol and the mean AUC(0, 24 h) and Cmax for levonorgestrel during ziprasidone co-administration were not statistically significantly different from corresponding values occurring during placebo co-administration."	( Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000)	1.96
"The findings of this study suggest that, based on pharmacokinetic and tolerability data, ziprasidone may be co-administered with ethinyloestradiol and levonorgestrel without loss of contraceptive efficacy or increased risk of adverse events."	( Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Anziano, RJ; Harness, J; Holt, PR; Muirhead, GJ; Oliver, S, 2000)	1.97
"The administration of cimetidine increased the ziprasidone AUC(0,infinity) by 6% but there were no statistically significant differences in Cmax, tmax or lambda(z) between the ziprasidone+cimetidine group and the ziprasidone group."	( The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Folger, CJ; Geoffroy, P; Hansen, RA; Wilner, KD, 2000)	0.87
" Pharmacokinetic data were obtained on days 3 and 28."	( The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Anziano, RJ; Hansen, RA; Laurent, A; Miceli, JJ; Robarge, L, 2000)	0.54
" Carbamazepine administration to group 1 was associated with modest reductions in ziprasidone exposure, with mean decreases in ziprasidone AUC(0,12 h) and Cmax values of 36% and 27%, respectively, on day 28 compared with day 3 (P<0."	( The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Anziano, RJ; Hansen, RA; Laurent, A; Miceli, JJ; Robarge, L, 2000)	0.77
" Ziprasidone pharmacokinetic parameters were compared between placebo and ketoconazole administration periods."	( The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. Laurent, A; Miceli, JJ; Morse, T; Robarge, L; Smith, M, 2000)	1.5
" Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively."	( The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. Laurent, A; Miceli, JJ; Morse, T; Robarge, L; Smith, M, 2000)	0.59
" This paper will review the literature concerning real and theoretical implications of pharmacokinetic and pharmacodynamic interactions with ziprasidone, particularly with regard to these effects on the QTc interval."	( Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Kelly, DL; Love, RC, 2001)	1.95
" The objective of this study was to probe the dopamine agonist and antagonist pharmacodynamic properties of ziprasidone in youth."	( Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. Gilbert, DL; Miceli, JJ; Robarge, L; Sallee, FR; Vinks, AA; Wilner, K, 2003)	0.86
" The IM pharmacokinetic profile was consistent between studies and linear, with dose-related increases in exposure observed."	( Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. Miceli, JJ; Swan, SK; Tensfeldt, TG; Wilner, KD, 2005)	0.57
" The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]	( Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Preskorn, SH, 2005)	0.84
" Regression analysis of AUC(0-infinity) and Cmax values versus weight-normalized dose showed linear, dose-related changes in ziprasidone exposure."	( Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. Miceli, JJ; Patel, NC; Robarge, L; Sallee, FR; Tensfeldt, T; Wilner, K, 2006)	0.8
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Pharmacokinetic interactions with comedication played a minor role."	( The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. Dietmaier, O; Gansmüller, R; Gründer, G; Hiemke, C; Leiblein, T; Vogel, F; Wassmuth, H, 2009)	0.74
" The pharmacokinetic parameters were analyzed by DAS software and the relative bioavailability was calculated according to the formula F=AUC(t)/AUC(r)x100%."	( [Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. Chen, QX; Huang, WQ; Liu, WZ; Wang, GF; Zhang, JJ, 2009)	0.61
" After intravenous injection, systemic clearance, steady-state volumes of distribution and half-life remained unaltered as a function of dose with values in the range 22."	( Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Chae, YJ; Koo, TS; Lee, KR, 2011)	0.37
" Furthermore, a systematic review of the clinical pharmacokinetic and pharmacodynamic properties and tolerability of ziprasidone was conducted to explain the meta-analytic findings."	( Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile. Létourneau, G; Moteshafi, H; Potvin, S; Stikarovska, I; Stip, E; Tourjman, V; Zhornitsky, S, 2011)	2.02
" The determination of the pharmacokinetic behavior of this drug is of utmost importance in evaluating its bioavailability."	( High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. Marghade, S; Moorkoth, S; Musmade, PB, )	0.38
" Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination."	( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties. Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013)	0.85
"Evidence was given that P-gp substrate properties have pharmacodynamic consequences for aripiprazole but not for ziprasidone and thus affect dopamine receptor related motor behaviour."	( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties. Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013)	0.86
" Pharmacokinetic parameters were derived from plasma concentrations of ziprasidone collected prior to and over the 48 h after each ziprasidone administration."	( Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2014)	0.85
" In this process, particular attention has been paid to the drug pharmacokinetic characteristics and its safety in clinical use."	( Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder. Mandrioli, R; Mercolini, L; Protti, M, 2015)	0.65
" Using GastroPlus™, a commercially available pharmacokinetic simulation software, a semiphysiological model-a kind of physiologically based pharmacokinetic (PBPK) absorption model-was developed that could predict the concentration-time profiles when ziprasidone was administered with any one of the five test meals or fasting."	( The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption. Gandelman, K; Nause, R; Sutton, SC, 2017)	0.87
"A full physiologically-based pharmacokinetic (PBPK) model of ziprasidone was developed and validated for the non-pregnant population (healthy adults, paediatrics, geriatrics), and this was extended to the pregnant state to assess the change in PK profile of ziprasidone throughout pregnancy."	( Physiologically-based pharmacokinetics of ziprasidone in pregnant women. Biesdorf, C; Diniz, A; Martins, FS; Sy, SKB, 2019)	1.02
" The use of physiologically based pharmacokinetic models has gained importance and is nowadays a standard tool for food effect predictions at preclinical and clinical stages in the pharmaceutical industry."	( Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug-Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models. Emami Riedmaier, A; Kesisoglou, F; Parrott, N; Pepin, XJH; Wagner, C, 2021)	0.62

Excerpt	Reference	Relevance
"Our data, showing that ziprasidone in combination with sertraline lead to a decrease of prolonged P3 latencies, are in line with previous studies showing a decrease of prolonged P3 latencies by antidepressant treatment."	( The impact of ziprasidone in combination with sertraline on visually-evoked event-related potentials in depressed patients with psychotic features. Arolt, V; Baune, BT; Dannlowski, U; Deckert, J; Evers, S; Hetzel, G; Moeller, O; Nguyen, DH, 2007)	1.01
" The need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine is the most common reason for simultaneously prescribing a second antipsychotic drug in combination with clozapine."	( Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Barbui, C; Boso, M; Cipriani, A, 2009)	0.35
"In a randomized trial, we recently obtained evidence for comparable efficacy and differential side effects of clozapine in combination with ziprasidone (CZ, N=12) versus risperidone (CR, N=12)."	( Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Dressing, H; Englisch, S; Krumm, B; Kuwilsky, A; Zink, M, 2010)	0.8
"The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process."	( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018)	0.68
"In vitro drug-drug interaction potential of test compounds was investigated in two stages; 1) assessment of CYP450 inhibition potential of test compounds using human liver microsomes (HLM); and 2) assessment of test compounds as substrate of Phase I enzymes; including CYP450, FMO, AO and MAO using HLM, recombinant human CYP enzymes (rhCYP), Human Liver Cytosol (HLC) and Human Liver Mitochondrial (HLMit)."	( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018)	0.68
", perpetrator and/or victim drug) to overcome any imminent risk of potential clinical drug-drug interaction when sulfoxide/sulfone metabolite(s) generating drugs are coadministered in therapy."	( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018)	0.68
" This 24-week randomized, double-blinded, controlled clinical trial randomly allocated 452 FEDN SCZ patients to receive a usual dose of ziprasidone (control group) or half the dose of ziprasidone in combination with sertraline (ZS group)."	( Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial. Guan, X; Kosten, TR; Liu, J; Wang, Y; Wu, F; Xiu, M; Zhang, X; Zhu, C, 2022)	1.34

Excerpt	Reference	Relevance
" It may be less well absorbed and/or less effective than Clozaril, although evidence is conflicting."	( Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP, 2002)	0.31
" Oral bioavailability of ziprasidone taken with food is approximately 60%, half-life is approximately 6-7 hours, and protein binding is extensive at >99%."	( Ziprasidone: the fifth atypical antipsychotic. Caley, CF; Cooper, CK, 2002)	2.06
" The mean bioavailability for the 5-mg IM ziprasidone dose was approximately 100%."	( Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. Miceli, JJ; Swan, SK; Tensfeldt, TG; Wilner, KD, 2005)	0.84
" The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]	( Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Preskorn, SH, 2005)	0.84
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"Oral ziprasidone bioavailability is increased when taken with food."	( The effect of food on the absorption of oral ziprasidone. Alderman, J; Glue, P; Miceli, JJ; Wilner, K, 2007)	1.11
"Food is known to increase the bioavailability of ziprasidone."	( The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. Alderman, JA; Gandelman, K; Glue, P; LaBadie, RR; Lombardo, I; Preskorn, SH; Versavel, M, 2009)	0.85
"These results confirm that ziprasidone should be taken with food and that a meal equal to or greater than 500 kcal, irrespective of fat content, is required for optimal and reproducible bioavailability of the administered dose."	( The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. Alderman, JA; Gandelman, K; Glue, P; LaBadie, RR; Lombardo, I; Preskorn, SH; Versavel, M, 2009)	0.9
"To investigate the pharmacokinetics and bioavailability of ziprasidone tablets in Chinese healthy volunteers."	( [Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. Chen, QX; Huang, WQ; Liu, WZ; Wang, GF; Zhang, JJ, 2009)	0.85
" The pharmacokinetic parameters were analyzed by DAS software and the relative bioavailability was calculated according to the formula F=AUC(t)/AUC(r)x100%."	( [Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. Chen, QX; Huang, WQ; Liu, WZ; Wang, GF; Zhang, JJ, 2009)	0.61
"ml(-1), respectively, with the relative bioavailability of (98."	( [Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. Chen, QX; Huang, WQ; Liu, WZ; Wang, GF; Zhang, JJ, 2009)	0.61
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
"Determining a drug dosing regimen that produces consistent bioavailability and patient effects is one of the goals of the drug development process."	( How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. Lincoln, J; Preskorn, SH; Stewart, ME, 2010)	0.57
"P-glycoprotein (Pgp or ABCB1) is an ABC transporter protein involved in intestinal absorption, drug metabolism, and brain penetration, and its inhibition can seriously alter a drug's bioavailability and safety."	( A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Goracci, L; Neri, A; Oprea, TI, 2011)	0.37
" It is well absorbed from the digestive tract and its absorption increases after the meal."	( [Practical aspects of the use of ziprasidone in schizophrenia]. Jarema, M; Ochedzan, D, )	0.41
" Pharmacokinetic studies were conducted with these formulations to examine the bioavailability of test formulations in fasted and fed state compared to commercial capsules (Geodon®) dosed in the fed state."	( Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Alderman, JA; Herbig, SM; Thombre, AG, 2011)	0.79
" Following oral administration, absolute oral bioavailability was not dose dependent with approximately 23%."	( Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Chae, YJ; Koo, TS; Lee, KR, 2011)	0.37
"The SD-ZIP osmotic pump tablet could be able to enhance the bioavailability in the fasted state and showed sustained release with prolonged actions."	( Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state. Guoguang, C; Lili, R; Pingkai, O; Yanfei, M, 2015)	0.73
"The purpose of this work was to develop self-nanomulsifying drug delivery systems (SNEDDS) in sustained-release pellets of ziprasidone to enhance the oral bioavailability and overcome the food effect of ziprasidone."	( Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect. Chen, G; Miao, Y; Pingkai, O; Ren, L, 2016)	0.86
" In order to achieve acceptable bioavailability and prolonged exposures for once-daily dosing, good colonic absorption and a reliable controlled release (CR) technology are necessary."	( Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone. Caldwell, WB; Connor, AL; Malhotra, BK; Shamblin, SL; Thombre, AG; Wilding, IR, 2015)	0.64
"The purpose of this work was to develop ziprasidone-phospholipid complex (ZIP-PLC) in sustained-release pellets to enhance the oral bioavailability and overcome the food effect of ziprasidone."	( Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect. Chen, G; Miao, Y; Ouyang, P; Ren, L, 2016)	0.99
"Ziprasidone is a poorly water-soluble antipsychotic drug that demonstrates low fasted state oral bioavailability and a clinically significant two-fold increase in absorption when dosed postprandially."	( Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro. Dening, TJ; Prestidge, CA; Rao, S; Thomas, N, 2016)	2.1
"In a recent food effect clinical study, the authors concluded that a meal consisting of ≥500 kcal, regardless of fat content, produced the maximal bioavailability for ziprasidone."	( The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption. Gandelman, K; Nause, R; Sutton, SC, 2017)	0.88
"The purpose of this study was to research a novel combination of Plasdone-S630 and HPMCAS-HF as hot-melt carrier used in ziprasidone hydrochloride for enhanced oral bioavailability and dismissed food effect."	( A Combined Utilization of Plasdone-S630 and HPMCAS-HF in Ziprasidone Hydrochloride Solid Dispersion by Hot-Melt Extrusion to Enhance the Oral Bioavailability and No Food Effect. Chen, G; Ren, L; Wang, J; Xu, X; Xue, X, 2019)	0.97
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" ZP possesses poor oral bioavailability (~50%), short biological half-life (~2."	( Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy. Ahmad, FJ; Ahmed, MZ; Hasan, N; Jain, GK; Khan, UA; Parveen, U; Saad, S, 2020)	0.8

Excerpt	Relevance	Reference
" However, risperidone induced a U-shaped dose-response curve."	( Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Skarsfeldt, T, 1995)	0.29
" RO was nearly complete at 4 hr after dosing (98%) and remained elevated at 18 hr (46%)."	( Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. Alpert, NM; Babich, JW; Bonab, AA; Elmaleh, DR; Fischman, AJ; Rauch, SL; Rubin, RH; Shoup, TM; Williams, SA, 1996)	0.49
" With increasing time between dosing and PET scanning there was a curvilinear increase in BP, so that all studies performed at or after 18 h post-dose gave BPs in the normal range (mean +/- 2 SD)."	( The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Bench, CJ; Boyce, M; Brannick, LY; Dolan, RJ; Frackowiak, RS; Grasby, PM; Gunn, KP; Lammertsma, AA; Warrington, SJ, 1996)	0.52
" Metabolites designated M6 and M9 were isolated from urine and bile of the rat dosed with radiolabeled ZIP and purified by reversed phase HPLC."	( Characterization of the novel benzisothiazole ring-cleaved products of the antipsychotic drug ziprasidone. Cui, D; Kamel, A; Prakash, C, 1997)	0.52
" An intramuscular dosage form of ziprasidone was developed using beta-cyclodextrin sulfobutyl ether (SBECD) to solubilize the drug by complexation."	( Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. Blake, JF; Chrunyk, B; Duffy, EM; Kim, Y; Massefski, W; Oksanen, DA, 1998)	0.88
" Ziprasidone was associated with transient prolactin elevation but levels of prolactin returned to baseline within the dosing interval at steady state."	( Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Apseloff, G; Gerber, N; Hansen, RA; Johnson, AC; Miceli, JJ; Wilner, KD, 2000)	1.48
" The initial evidence suggests an effective dosage range of 80-160 mg/day."	( Focus on ziprasidone. Green, B, 2001)	0.73
" The initial evidence suggests an effective dosage range of 80-160 mg/day."	( Brief report on Ziprasidone. Chowdhury, WA; Firoz, AH; Mamun, AA; Rahman, AH, 2002)	0.66
" Unfortunately, this type of drugs cannot block the D2 receptors only in the mesolimbic dopaminergic pathway (which mediates their therapeutic effects), because of their non-selective D2 receptor blockage in both the mesolimbic and striatal regions, and the consequent appearance of side effects related to striatal interaction in the same dosage range as is needed for the therapeutical effects."	( New antipsychotics and schizophrenia: a review on efficacy and side effects. Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A, 2004)	0.32
" Subjects who had received intramuscular ziprasidone were identified, and their age, gender, and dosage were recorded."	( Intramuscular ziprasidone in youth: a retrospective chart review. Staller, JA, 2004)	0.95
" Several issues remain to be addressed, including the efficacy of once-daily dosing, the need to take the medication with food, and the correct dosing strategy."	( Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Bowie, CR; Harvey, PD, 2005)	1.77
" Mice were acclimated to individual housing, given ad libitum access to chow and water, dosed with placebo peanut butter pills for 1 week, and then dosed daily with AAPD-laced peanut butter pills for 4 weeks."	( Antipsychotic drug-induced weight gain: development of an animal model. Allison, DB; Casey, DE; Cope, MB; Fernández, JR; Geary, N; Nagy, TR, 2005)	0.33
" Dosage alterations of olanzapine and clozapine, dependent on cytochrome P450 1A2 (CYP1A2) for clearance, and quetiapine, dependent on cytochrome P450 3A (CYP3A), may be necessary when used with other drugs that inhibit or induce their metabolic enzymes."	( The dosing of atypical antipsychotics. Armstrong, SC; Cozza, KL; de Leon, J, )	0.13
"The purpose of this study was to provide single-dose pharmacokinetic, safety, and tolerability data for ziprasidone in youths with tic disorder, for comparison to adult studies to discern whether ziprasidone pediatric dosing could be modeled from adult data."	( Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. Miceli, JJ; Patel, NC; Robarge, L; Sallee, FR; Tensfeldt, T; Wilner, K, 2006)	0.81
" Dosing of ziprasidone oral suspension (40 mg/mL) was weight adjusted: >60 kg, 20 mg (group 1, n = 8); 31 to 60 kg, 10 mg (group 2, n = 8); and 16 to 30 kg, 5 mg (group 3, n = 8)."	( Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. Miceli, JJ; Patel, NC; Robarge, L; Sallee, FR; Tensfeldt, T; Wilner, K, 2006)	0.99
" In adult patients with schizophrenia or schizoaffective disorder, oral ziprasidone was effective at a dosage of 40-80 mg twice daily in patients experiencing a phase of acute illness, and at a dosage of 20-80 mg twice daily in those with chronic schizophrenia or schizoaffective disorder, including those who were symptomatically stable."	( Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Scott, LJ; Swainston Harrison, T, 2006)	2.01
" Dosing between children and adolescents significantly differed in the olanzapine group, whereas dosing was comparable in the ziprasidone group."	( A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. Khan, SS; Mican, LM, 2006)	0.8
" The study required fixed dosing with ziprasidone."	( [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics]. Bartkó, G; Bitter, I; Degrell, I; Faludi, G; Füredi, J; Trixler, M, 2006)	0.87
" Ziprasidone dosage ranged from 20 to 160 mg/day (mean, 98."	( Ziprasidone in adolescents with autism: an open-label pilot study. Cater, JR; Delaney, MA; Hyman, SB; Malone, RP, 2007)	2.69
" Half maximal effective concentration values were consistently higher in striatal than in extrastriatal regions (temporal cortex: 39 ng/mL; putamen: 64 ng/mL), irrespective of the time between last dosing and scan."	( Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). Bartenstein, P; Boy, C; Bröcheler, A; Buchholz, HG; Cumming, P; Fellows, C; Gründer, G; Hiemke, C; Janouschek, H; Landvogt, C; Rösch, F; Schäfer, W; Spreckelmeyer, K; Vernaleken, I; Veselinovic, T; Wong, DF, 2008)	0.58
"Community dwelling patients with schizophrenia were randomized to treatment with haloperidol (n=47) or ziprasidone dosed either once or twice daily (n=139)."	( Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. Harvey, PD; Kremer, CM; Lombardo, I; Pappadopulos, E, 2009)	0.78
" Occasional mild hypomania responded to dosage reduction."	( Ziprasidone monotherapy in bipolar II depression: an open trial. Akhtar, J; Dunner, D; Johnson, AE; Liebowitz, MR; Mech, A; Pratap, R; Salmán, E, 2009)	1.8
"Consistent with previous reports, higher doses of ziprasidone (120-160 mg/d, dosed twice daily with meals) are associated with significantly lower all-cause discontinuation rates and more favorable NNTs versus placebo."	( Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Citrome, L; Glue, P; Karayal, ON; Yang, R, 2009)	1.01
" A secondary objective of this case series was to attempt to establish an age-specific dosage and identify possible side effects of this medication."	( Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article. Conrad, SA; Green, R; McCarthy, PJ; Scott, LK, 2009)	0.57
" The preferred switch strategy was immediate discontinuation, and the preferred dosing regimen was 120 mg/day."	( Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A, 2009)	0.62
"Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration."	( Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Barbui, C; Boso, M; Cipriani, A, 2009)	0.35
"The purpose of this article is to review the utilization and dosing of ziprasidone in a state hospital system and to compare the dosing to dosing recommendations contained in product labeling that suggest a starting dose of 40 mg/day and a target dose range of 40 to 160 mg/day for schizophrenia."	( How dosing of ziprasidone in a state hospital system differs from product labeling. Citrome, L; Jaffe, A; Levine, J, 2009)	0.95
" Mean time to discontinuation was evaluated across propensity score-matched dosing groups."	( Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Citrome, L; Cuffel, B; Harnett, J; Lenhart, G; Montejano, LB; Palmer, L; Reist, C; Sanders, KN, 2009)	0.67
" Among the propensity score-matched dosing groups, the respective mean time to discontinuation for low, medium, and high doses was 90."	( Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Citrome, L; Cuffel, B; Harnett, J; Lenhart, G; Montejano, LB; Palmer, L; Reist, C; Sanders, KN, 2009)	0.67
" The switch from conventional antipsychotics to ziprasidone was achieved using one of three discrete schedules: (1) abrupt discontinuation of conventional antipsychotics on day 1; (2) fast taper-50% of conventional antipsychotic dosage on days 1 through 7, followed by discontinuation and (3) slow taper-100% of conventional antipsychotic dosage on days 1 and 2, followed by 50% on days 3 through 7, then discontinuation."	( Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Potvin, S; Stip, E; Tourjman, V; Zhornitsky, S, 2010)	0.87
"Determining a drug dosing regimen that produces consistent bioavailability and patient effects is one of the goals of the drug development process."	( How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone. Lincoln, J; Preskorn, SH; Stewart, ME, 2010)	0.57
" Seventy-three subjects with treatment-resistant GAD were recruited, and 62 were randomized to either ziprasidone or placebo treatment at a ratio of 2:1 using a flexible dosing strategy (20-80 mg daily)."	( Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. Etemad, B; Gallop, R; Lohoff, FW; Mandos, LA; Rickels, K, 2010)	2.02
" The proposed methods were applied for the determination of ziprasidone from pharmaceutical dosage forms and human serum samples without any time-consuming extraction, separation, evaporation or adsorption steps prior to drug assay except precipitation of the proteins using acetonitrile."	( Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes. Gumustas, M; Kul, D; Ozkan, SA; Uslu, B, 2010)	0.85
"This article addresses points to consider when switching patients to the second-generation antipsychotic (SGA), ziprasidone, in everyday clinical practice: 1) the pharmacologic properties of the pre-switch antipsychotic and of ziprasidone; 2) switch and dosing strategies to ensure maintenance or attainment of efficacy; 3) recognition and management of possible rebound effects of the pre-switch medication discontinuation; 4) recognition and management of potential side effects of ziprasidone; and 5) education and support for patients/caregivers concerning correct ziprasidone administration."	( Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Cañas, F; Correll, CU; Fagiolini, A; Larmo, I; Levy, P; Montes, JM; Papageorgiou, G; Rossi, A; Sturlason, R; Zink, M, 2011)	0.81
" We found substantial differences in baseline characteristics of subjects, administered dosage and disease severity in India compared to the USA and Russia."	( Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. Lombardo, I; Mandel, FS; Pappadopulos, E; Vieta, E, 2011)	0.59
" Pharmacokinetic studies were conducted with these formulations to examine the bioavailability of test formulations in fasted and fed state compared to commercial capsules (Geodon®) dosed in the fed state."	( Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Alderman, JA; Herbig, SM; Thombre, AG, 2011)	0.79
" Two formulations when taken in the fasted or fed state were comparable to the commercial capsules dosed in the fed state with respect to total exposure."	( Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Alderman, JA; Herbig, SM; Thombre, AG, 2011)	0.79
" Such formulations could provide simple and convenient dosing while retaining the familiar safety and efficacy profile of currently marketed capsules."	( Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Alderman, JA; Herbig, SM; Thombre, AG, 2011)	0.79
" The proposed validated method is convenient and reliable for the assay and purity control in both raw materials and dosage forms."	( Development and validation of an HPLC method for determination of ziprasidone and its impurities in pharmaceutical dosage forms. Agbaba, D; Malesevic, M; Nikolic, K; Pavlovic, M, )	0.37
"The present meta-analysis examined premature study discontinuation (PSD) and dose-response associated with ziprasidone."	( Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile. Létourneau, G; Moteshafi, H; Potvin, S; Stikarovska, I; Stip, E; Tourjman, V; Zhornitsky, S, 2011)	2.03
" In the patient with laryngeal dystonia these symptoms appeared after restarting risperidone treatment, in the other patient after diminishing the dosage of risperidone and adding sertindole, and in the third patient the syndrome appeared after beginning ziprasidone."	( Pisa syndrome and laryngeal dystonia induced by novel antipsychotics. Lerner, V; Miodownik, C; Witztum, E, 2011)	0.55
" Iloperidone 4-8, 10-16, and 20-24 mg/day (all dosed twice daily) were compared with placebo."	( Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome, L; Hochfeld, M; Meng, X; Stahl, SM, 2012)	0.38
" The final mean dosage for clozapine was 32."	( Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Baillés, E; Martí, MJ; Muñiz, A; Pintor, L; Tolosa, E; Valldeoriola, F, )	1.57
"Optimization of the experimental conditions of a novel HPLC method for determination of the impurity levels with ziprasidone (in bulk substance and pharmaceutical dosage forms) was performed with use of Multi-Layer Perceptron (MLP) Artificial Neural Networks (ANN) and Response Surface Plots."	( The chemometric study and quantitative structure retention relationship modeling of liquid chromatography separation of ziprasidone components. Agbaba, D; Nikolic, K; Pavlovic, M; Smolinski, A, 2012)	0.8
"These analyses confirm the effectiveness of ziprasidone (80-160mg/day) in preventing relapses in subjects with bipolar disorder, with the 120mg/day dosage appearing to have the highest relapse prevention rate."	( Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications. Bowden, CL; Gundapaneni, BK; Karayal, ON; O'Gorman, C; Schwartz, JH, 2013)	0.88
"Ultra Performance Liquid Chromatography (UPLC) was employed to develop a rapid and robust method for the analysis of ziprasidone, both as a drug substance and in the final dosage forms."	( Development of rapid and robust stability-indicating method for analysis of ziprasidone (hydrochloride and freebase) as drug substance and in medicines by UPLC. Cal, K; Zakowiecki, D, )	0.57
"Reducing the absorption difference between fed and fasted states is an important goal in the development of pharmaceutical dosage forms."	( Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state. Caldwell, WB; Friesen, DT; McCray, SB; Sutton, SC; Thombre, AG, 2012)	0.65
"All trials were industry supported, with some variability in dosage of haloperidol."	( Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013)	0.39
"The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg."	( Gingival pain: an unusual side effect of ziprasidone. Raghunath, A, 2013)	0.87
" The analysis reveals that general score from Positive and Negative Syndrome Scale (PANSS), cholesterol LDL, subjective well-being under neuroleptic, Simpson-Angus Scale (SAS) delta scores, drug dosage and premorbid intelligence entered in the equation."	( Short-term remission in schizophrenia as a combination of several outcome measures. Rossi, A; Stratta, P, 2013)	0.39
" Available experimental evidences and published patents are indicative of broadening the circle of the applications in point of both technological advantages and dosage forms."	( [Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin]. Sebestyén, Z; Szabó, B; Szepesi, K, 2013)	0.39
" Plasma concentrations of armodafinil and its circulating metabolites, R-modafinil acid and modafinil sulfone, were also obtained after repeated daily dosing of armodafinil alone."	( Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2014)	0.62
" The novel test methods simulate additional elements of mechanical and hydrodynamic stresses, which have an impact on solid oral dosage forms, especially during gastric emptying."	( The improvement of the dissolution rate of ziprasidone free base from solid oral formulations. Adrjanowicz, K; Cal, K; Garbacz, G; Kaminska, E; Kaminski, K; Swinder, L; Zakowiecki, D, 2015)	0.68
"Ziprasidone, like many BCS Class II drugs with low intrinsic solubility and a strong tendency to crystallize from supersaturated solutions, presents significant technical challenges when developing an oral controlled release dosage form."	( Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone. Caldwell, WB; Connor, AL; Malhotra, BK; Shamblin, SL; Thombre, AG; Wilding, IR, 2015)	2.08
"Ziprasidone is a poorly water-soluble antipsychotic drug that demonstrates low fasted state oral bioavailability and a clinically significant two-fold increase in absorption when dosed postprandially."	( Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro. Dening, TJ; Prestidge, CA; Rao, S; Thomas, N, 2016)	2.1
" Limited data exist on the pediatric dosing of ziprasidone in the emergency department (ED)."	( Intramuscular Ziprasidone Dosing for Acute Agitation in the Pediatric Emergency Department: An Observational Study. Foster, R; Nguyen, T; Stanton, J, 2018)	1.1
"To characterize the mg/kg dosing differences between pediatric ED patients who respond to an initial dose of ziprasidone versus patients who do not."	( Intramuscular Ziprasidone Dosing for Acute Agitation in the Pediatric Emergency Department: An Observational Study. Foster, R; Nguyen, T; Stanton, J, 2018)	1.05
" Secondary objectives were to identify the patient population in which ketamine was initiated, assess the proportion of time patients were at their goal level of sedation, and determine the dosing patterns of adjunctive sedative agents."	( Impact of Ketamine Use on Adjunctive Analgesic and Sedative Medications in Critically Ill Trauma Patients. Chui, SJ; Harbourt, K; Pajoumand, M; Pruskowski, KA; Reynolds, HN, 2017)	0.46
"The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau."	( Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S, 2020)	0.56
" In conclusion, the novel formulation of ZHM nanocrystal-based ODTs was successfully developed for alternative dosage form."	( Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. Celebi, N; Karakucuk, A; Tashan, E, 2020)	0.86
"MK801 dose-response study was conducted in RHA and Roman Low-Avoidance (RLA) male rats."	( Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features. Cañete, T; Fernández-Teruel, A; Lavín, V; Oliveras, I; Río-Álamos, C; Sampedro-Viana, D; Sánchez-González, A; Sanna, F; Tapias-Espinosa, C; Tobeña, A; Torrecilla, P, 2023)	0.91

Role	Description
psychotropic drug	A loosely defined grouping of drugs that have effects on psychological function.
histamine antagonist	Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.
muscarinic antagonist	A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
serotonergic antagonist	Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
dopaminergic antagonist	A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
antipsychotic agent	Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
piperazines
organochlorine compound	An organochlorine compound is a compound containing at least one carbon-chlorine bond.
indolones
1,2-benzisothiazole	A benzothiazole consisting of a benzene ring fused to an isothiazole.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	13.8029	0.0025	41.7960	15,848.9004	AID1347398
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	26.8325	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	15.4098	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
TDP1 protein	Homo sapiens (human)	Potency	27.6959	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	26.7797	0.0007	14.5928	83.7951	AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	18.8541	0.1800	13.5574	39.8107	AID1460; AID1468
AR protein	Homo sapiens (human)	Potency	23.2919	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	31.6228	0.1000	22.9075	100.0000	AID485364
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	14.7122	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	31.6704	0.0004	17.9460	75.1148	AID1346784; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	15.0423	0.0123	7.9835	43.2770	AID1346984; AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	22.8465	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	20.1260	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	21.1317	0.0030	41.6115	22,387.1992	AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	8.3299	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	21.8433	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	23.4105	0.3758	27.4851	61.6524	AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	11.8832	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	23.4352	0.0002	29.3054	16,493.5996	AID1259248; AID743069; AID743075; AID743078; AID743079; AID743091
G	Vesicular stomatitis virus	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	9.7717	0.0010	8.3798	61.1304	AID1645840
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	50.1187	0.7079	36.9043	89.1251	AID504333
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	22.6856	0.0010	24.5048	61.6448	AID743212; AID743215
arylsulfatase A	Homo sapiens (human)	Potency	37.9330	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	22.3872	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	19.7989	0.0007	23.0674	1,258.9301	AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	22.6874	0.0017	23.8393	78.1014	AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	26.8325	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	23.9145	0.0578	21.1097	61.2679	AID1159526
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	1.4125	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	23.2143	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	33.4889	0.0420	27.3789	61.6448	AID743210; AID743228
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	4.4668	0.0079	8.2332	1,122.0200	AID2551
Interferon beta	Homo sapiens (human)	Potency	12.3018	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	26.6032	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	26.6032	0.0119	12.2221	68.7989	AID651632
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	12.3018	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 3E	Homo sapiens (human)	Ki	0.3981	0.0010	0.8835	9.9000	AID298488
5-hydroxytryptamine receptor 3B	Homo sapiens (human)	Ki	0.3981	0.0010	0.8711	9.9000	AID298488
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	5.0000	0.0000	0.6902	10.0000	AID141100
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	Ki	5.0000	0.0000	0.7951	9.1201	AID141100
Cytochrome P450 3A4	Homo sapiens (human)	Ki	0.0610	0.0001	1.4162	9.9000	AID599884
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	0.0094	0.0001	0.5326	10.0000	AID1393366; AID298481; AID313956; AID342783; AID3657
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	Ki	5.0000	0.0000	0.7292	6.9183	AID141100
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	0.3900	0.0001	0.8074	10.0000	AID36197; AID36199
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	Ki	6.7000	0.0000	0.5972	9.1201	AID141100; AID141174; AID342774
D(2) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	0.0050	0.0000	0.7472	8.0000	AID254688
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.0042	0.0000	0.6518	10.0000	AID1054120; AID1393368; AID1430534; AID1520010; AID1556426; AID1595147; AID298478; AID313953; AID342777; AID63060; AID63070; AID714109
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	Ki	0.0004	0.0001	0.6017	10.0000	AID5328
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0200	0.0001	0.9490	10.0000	AID298478; AID36016; AID3657
Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)	IC50 (µMol)	5.3900	5.3900	5.3900	5.3900	AID1850916
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	0.3900	0.0002	0.7257	10.0000	AID36197; AID36199
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.3900	0.0003	0.4834	10.0000	AID36197; AID36199
D	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1514	0.0003	0.5026	7.7625	AID243189
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1514	0.0003	1.0914	7.7625	AID243189
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	Ki	5.0000	0.0000	0.5405	7.7600	AID141100
D(1A) dopamine receptor	Homo sapiens (human)	Ki	0.1565	0.0001	0.8363	10.0000	AID342775; AID63345; AID63347
D(4) dopamine receptor	Homo sapiens (human)	Ki	0.0400	0.0000	0.4362	10.0000	AID298480; AID342779; AID61808; AID63537
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1514	0.0003	1.0914	7.7625	AID243189
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1514	0.0003	1.0691	7.7625	AID243189
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0200	0.0000	0.5751	10.0000	AID298478; AID36016; AID3657
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1514	0.0007	0.9774	9.7000	AID243189
Alpha-1D adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0002	0.7568	8.8970	AID254726
Alpha-1D adrenergic receptor	Homo sapiens (human)	Ki	0.0090	0.0000	0.3609	10.0000	AID1054113; AID1682829; AID36113; AID36116
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0001	0.8801	8.8500	AID254754
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	0.0005	0.0000	0.3855	10.0000	AID1054119; AID1393364; AID298482; AID313955; AID342784; AID5197; AID5199
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	0.0050	0.0001	0.9549	10.0000	AID1054116; AID298485; AID342781; AID5614; AID5616; AID599883
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.0662	0.0000	0.7048	8.1930	AID298489; AID342787
5-hydroxytryptamine receptor 7	Homo sapiens (human)	Ki	0.0053	0.0003	0.3806	10.0000	AID1054114; AID1393367; AID298487
Alpha-1A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0002	0.5614	5.4000	AID254726
Alpha-1A adrenergic receptor	Homo sapiens (human)	Ki	0.0090	0.0000	0.2726	10.0000	AID1054113; AID1682829; AID36113; AID36116
Histamine H1 receptor	Homo sapiens (human)	Ki	0.1531	0.0000	0.5110	10.0000	AID1682828; AID342782; AID87226; AID87242
Alpha-1B adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0110	0.0002	0.6526	8.3300	AID254726
Alpha-1B adrenergic receptor	Homo sapiens (human)	Ki	0.0090	0.0000	0.4713	10.0000	AID1054113; AID1682829; AID36113; AID36116
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.0076	0.0000	0.6020	10.0000	AID1054117; AID298479; AID342778; AID65121; AID65785
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	0.0016	0.0003	0.7693	10.0000	AID298483
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0151	0.0000	0.9650	10.0000	AID298478; AID313957; AID36016; AID3657
5-hydroxytryptamine receptor 3A	Homo sapiens (human)	Ki	0.3981	0.0000	0.7411	9.9000	AID298488
5-hydroxytryptamine receptor 6	Homo sapiens (human)	Ki	0.0562	0.0002	0.5229	10.0000	AID1054115; AID1393365; AID298486; AID342773; AID599884
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Rattus norvegicus (Norway rat)	Ki	0.0130	0.0010	0.0163	0.0330	AID599883
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.0048	0.0000	0.4375	10.0000	AID63811; AID65713
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	0.2301	0.0009	1.9014	10.0000	AID222148; AID243151; AID243189; AID397743; AID408340; AID420668; AID539465; AID576612
Transporter	Rattus norvegicus (Norway rat)	Ki	0.0480	0.0001	0.7629	5.5000	AID342786
5-hydroxytryptamine receptor 3D	Homo sapiens (human)	Ki	0.3981	0.0010	0.8835	9.9000	AID298488
5-hydroxytryptamine receptor 3C	Homo sapiens (human)	Ki	0.3981	0.0010	0.8835	9.9000	AID298488
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
D(2) dopamine receptor	Homo sapiens (human)	Activity	0.0097	0.0097	0.5849	2.0000	AID1506227
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Activity	0.0003	0.0003	0.0043	0.0071	AID1506226
Histamine H1 receptor	Homo sapiens (human)	Activity	0.0430	0.0012	0.0475	0.0982	AID1506225
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cell surface receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gastric acid secretion	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dopamine transport	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
transmission of nerve impulse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylation	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	D(2) dopamine receptor	Homo sapiens (human)
regulation of locomotion involved in locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cellular response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor production	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	D(2) dopamine receptor	Homo sapiens (human)
hyaloid vascular plexus regression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of neuron migration	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(2) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
gluconeogenesis	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
2-oxoglutarate metabolic process	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
oxaloacetate metabolic process	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
glycerol biosynthetic process	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
aspartate metabolic process	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
aspartate catabolic process	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
glutamate metabolic process	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
Notch signaling pathway	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
glutamate catabolic process to aspartate	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
glutamate catabolic process to 2-oxoglutarate	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
cellular response to insulin stimulus	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
response to glucocorticoid	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
fatty acid homeostasis	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
aspartate biosynthetic process	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of blood pressure	Alpha-2B adrenergic receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
calcium-mediated signaling	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synaptic transmission, cholinergic	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of insulin secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein modification process	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
temperature homeostasis	D(1A) dopamine receptor	Homo sapiens (human)
conditioned taste aversion	D(1A) dopamine receptor	Homo sapiens (human)
behavioral fear response	D(1A) dopamine receptor	Homo sapiens (human)
regulation of protein phosphorylation	D(1A) dopamine receptor	Homo sapiens (human)
synaptic transmission, dopaminergic	D(1A) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(1A) dopamine receptor	Homo sapiens (human)
protein import into nucleus	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	D(1A) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
activation of adenylate cyclase activity	D(1A) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathway	D(1A) dopamine receptor	Homo sapiens (human)
synapse assembly	D(1A) dopamine receptor	Homo sapiens (human)
memory	D(1A) dopamine receptor	Homo sapiens (human)
mating behavior	D(1A) dopamine receptor	Homo sapiens (human)
grooming behavior	D(1A) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(1A) dopamine receptor	Homo sapiens (human)
visual learning	D(1A) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(1A) dopamine receptor	Homo sapiens (human)
astrocyte development	D(1A) dopamine receptor	Homo sapiens (human)
dopamine transport	D(1A) dopamine receptor	Homo sapiens (human)
transmission of nerve impulse	D(1A) dopamine receptor	Homo sapiens (human)
neuronal action potential	D(1A) dopamine receptor	Homo sapiens (human)
dentate gyrus development	D(1A) dopamine receptor	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
L-aspartate:2-oxoglutarate aminotransferase activity	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
phosphatidylserine decarboxylase activity	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
pyridoxal phosphate binding	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
L-cysteine transaminase activity	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gs	D(1A) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
protein binding	D(1A) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine binding	D(1A) dopamine receptor	Homo sapiens (human)
arrestin family protein binding	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(4) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(4) dopamine receptor	Homo sapiens (human)
protein binding	D(4) dopamine receptor	Homo sapiens (human)
potassium channel regulator activity	D(4) dopamine receptor	Homo sapiens (human)
SH3 domain binding	D(4) dopamine receptor	Homo sapiens (human)
dopamine binding	D(4) dopamine receptor	Homo sapiens (human)
identical protein binding	D(4) dopamine receptor	Homo sapiens (human)
metal ion binding	D(4) dopamine receptor	Homo sapiens (human)
epinephrine binding	D(4) dopamine receptor	Homo sapiens (human)
norepinephrine binding	D(4) dopamine receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	D(4) dopamine receptor	Homo sapiens (human)
neurotransmitter receptor activity	D(4) dopamine receptor	Homo sapiens (human)
serotonin binding	D(4) dopamine receptor	Homo sapiens (human)
protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
identical protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1D adrenergic receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
protein binding	Alpha-1B adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1B adrenergic receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
histamine receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 6	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
cell surface	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
nucleus	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
cytoplasm	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
cytosol	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
extracellular exosome	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
cytosol	Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nucleus	D(1A) dopamine receptor	Homo sapiens (human)
endoplasmic reticulum membrane	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
cilium	D(1A) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
dendritic spine	D(1A) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(1A) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(1A) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
centrosome	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(4) dopamine receptor	Homo sapiens (human)
membrane	D(4) dopamine receptor	Homo sapiens (human)
postsynapse	D(4) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	D(4) dopamine receptor	Homo sapiens (human)
dendrite	D(4) dopamine receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
trans-Golgi network membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
nucleus	Alpha-1B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1B adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1B adrenergic receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
cleavage furrow	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
cilium	5-hydroxytryptamine receptor 6	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 6	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1653802	Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 200 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID254754	Inhibitory concentration against 5-hydroxytryptamine 2 receptor	2005	Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21	Designed multiple ligands. An emerging drug discovery paradigm.
AID330554	Increase in phospho-AMPK level in paraventricular hyphalamic nuclei intact H1RKO mouse at 3 mg/kg, ip after 3 hrs by immunohistochemistry	2007	Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9	From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36199	Binding affinity towards human alpha-2 adrenergic receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID36116	Binding affinity towards human alpha-1 adrenergic receptor	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID1215943	Metabolic stability in human intestinal S9 fraction assessed as compound remaining at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID298490	Displacement of [3H]pirenzepine from human M1 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1393476	Effect on failure incidence during conditioned avoidance response test in ip dosed Sprague-Dawley rat administered 60 mins prior to testing
AID3657	Binding affinity towards human 5-hydroxytryptamine 1 receptor	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1682829	Binding affinity to adrenergic alpha1 receptor (unknown origin)
AID1393482	Reversal of ketamine-induced working social withdrawal in Sprague-Dawley rat at 1 mg/kg, ip pretreated for 60 mins followed by ketamine administration
AID63060	Binding affinity towards human Dopamine receptor D2	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID176744	Dose inhibiting conditioned avoidance response in rats after oral administration	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID539465	Inhibition of human ERG	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID714088	Increase in DOPAC level in Sprague-Dawley rat striatum at 6.4 umol/kg, sc by HPLC analysis relative to saline-treated control	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID374351	Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.
AID63347	Binding affinity towards human Dopamine receptor D1	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID342778	Binding affinity to human cloned dopamine D3 receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID420668	Inhibition of human ERG in MCF7 cells	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID141100	Binding affinity towards human muscarinic receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID313956	Displacement of [3H]8OHDPAT from human 5HT1A receptor	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	1-Aminoindanes as novel motif with potential atypical antipsychotic properties.
AID176735	Dose (administered orally) inhibiting spontaneous locomotor behavior in rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID1653792	Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 200 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID313953	Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	1-Aminoindanes as novel motif with potential atypical antipsychotic properties.
AID342781	Binding affinity to human cloned 5HT2C receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID342783	Binding affinity to human cloned 5HT1A receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1054116	Binding affinity to 5HT2C receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1215949	Metabolic stability in human intestinal cytosol at 200 nM after 60 mins in presence of menadione	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID705396	Antipsychotic activity in sc dosed rat prepulse inhibition model	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
AID298480	Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID669782	Antibacterial activity against Staphylococcus aureus SA-1199B harboring grlA A116E mutant by microdilution techniques	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID298488	Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1393472	Antipsychotic activity in ip dosed Sprague-Dawley rat assessed as suppression of avoidance behavior by avoiding foot shock administered 60 mins prior to test by conditioned avoidance response test
AID539464	Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID420669	Lipophilicity, log D at pH 7.0	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1215940	Unbound intrinsic clearance in human liver S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID342774	Binding affinity to human cloned muscarinic M1 receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1393366	Displacement of [3H]-8-OH-DPAT from human 5-HT1AR expressed in HEK293 cell membranes after 1 hr by microbeta counting method
AID1054120	Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1653797	Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 200 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID313958	Displacement of [3H]dofetilide from human ERG channel expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	1-Aminoindanes as novel motif with potential atypical antipsychotic properties.
AID330537	Increase in phospho-AMPK levels in H1RKO mouse hyphalamic slices at 500 nM after 30 mins by Western blotting	2007	Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9	From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID342782	Binding affinity to human cloned histamine H1 receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1595147	Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method
AID1682828	Binding affinity to H1 histamine receptor (unknown origin)
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID176743	Dose inducing catalepsy in rats after oral administration	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID1393467	Toxicity in Wistar rat assessed as increase in prolactin level at 3 mg/kg, po after 60 mins by ELISA
AID1215955	Apparent permeability of the compound at 50 uM at pH 7.4 after 240 mins by PAMPA	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1215938	Unbound intrinsic clearance in human liver cytosol at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID63537	Binding affinity towards human dopamine receptor D4	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID176734	Dose (administered orally) inhibiting apomorphine-induced stereotypy in rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID5614	Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID1215935	Unbound intrinsic clearance in human intestinal microsomes at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID599884	Displacement of [3H]5-LSD from human 5HT6 receptor expressed in human HeLa cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
AID63345	Binding affinity against dopamine receptor D1	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID468443	Inhibition of human FAAH at 1 uM	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1215939	Unbound intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1556426	Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	2-Aminoimidazole-based antagonists of the 5-HT
AID1578090	Unbound brain-to-plasma concentration ratio in rat	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
AID254726	Inhibitory concentration against alpha adrenergic receptor	2005	Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21	Designed multiple ligands. An emerging drug discovery paradigm.
AID1054114	Binding affinity to 5HT7 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID5199	Binding affinity for human 5-hydroxytryptamine 2A receptor	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID419436	Lipophilicity, log P of the compound	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect.
AID705400	Antipsychotic activity in sc dosed rat by conditioned avoidance response test	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
AID714109	Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID35277	Displacement of [3H]prazosin from Alpha-1 adrenergic receptor in rat brain	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID65713	Displacement of [3H]NPA from rat brain Dopamine receptor D2	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID714104	Increase in DOPAC level in sc dosed Sprague-Dawley rat striatum by HPLC analysis	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID714107	Displacement of [3H]imipramine from human SERT expressed in CHO cells by competition binding assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID714105	Displacement of [3H]Ro 41-1049 from MAO-A in rat cerebral cortex by competition binding assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID36197	Binding affinity towards human alpha-2 adrenergic receptor	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID231369	Ratio representing inhibitory activity against catalepsy to inhibitory activity against amphetamine-induced locomotor behavior in rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1193218	Displacement of [3H]-SB269970 from 5-HT7 receptor (unknown origin) at 10 uM after 60 mins	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	In vitro and in silico evaluation of twelve newly-synthesized 1-acetamide-5-methoxy-2-oxindoles as 5-Ht₇ receptor ligands.
AID342786	Binding affinity to rat NET	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID36016	Displacement of [3H]prazosin from rat brain Alpha-1 adrenergic receptor	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID1054119	Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID231370	Ratio representing inhibitory activity against spontaneous locomotor behavior to inhibitory activity against amphetamine-induced stereotypy in rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID705399	Antipsychotic activity in sc dosed rat assessed as decrease in spontaneous locomotor activity	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
AID227557	In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID298492	Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID65785	Binding affinity towards human Dopamine receptor D3	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID342773	Binding affinity to human cloned 5HT6 receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1393468	Antipsychotic activity in ip dosed Sprague-Dawley rat assessed as reduction in PCP-induced hyper-locomotion pretreated for 60 mins followed by PCP addition measured for 30 mins starting 15 min after rat reintroduction to auto-tracks
AID1215944	Intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID227559	Relative binding affinity for dopamine D2 and alpha receptors	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID705398	Antipsychotic activity in sc dosed rat assessed as decrease in phencyclidine-induced locomotor activity	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
AID298486	Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1393475	Reversal of ketamine-induced cognitive flexibility in ip dosed Sprague-Dawley rat administered 30 mins prior to ketamine administration by attentional set-shifting test
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID539466	Solubility of the compound	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID313955	Displacement of [3H]ketanserin from human 5HT2A receptor expressed in Swiss 3T3 cells	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	1-Aminoindanes as novel motif with potential atypical antipsychotic properties.
AID1506227	Binding affinity to DRD2 (unknown origin)
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1215947	Unbound intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis in presence of NADH	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1393365	Displacement of [3H]-LSD from human 5-HT6R expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method
AID1506225	Binding affinity to HRH1 (unknown origin)
AID397743	Inhibition of human ERG channel	2009	Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14	Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1215948	Unbound intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis in presence of NADPH	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID87226	Binding affinity towards human H1 receptor	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID342779	Binding affinity to human cloned dopamine D4 receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1215936	Unbound intrinsic clearance in human liver microsomes at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID298491	Displacement of [3H]4-DAMP from human M4 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID330561	Displacement of [3H]mepyramine from H1R in rat brain	2007	Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9	From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
AID714108	Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID1393369	Selectivity index, ratio of pKi for 5-HT2AR to pKi for human D2LR
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID298489	Displacement of [3H]paraxetine from human 5HT transporter expressed in HEK293 cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID5573	Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID298478	Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID669779	Inhibition of norA-mediated ethidium bromide efflux in Staphylococcus aureus SA-1199B harboring grlA A116E mutant at 50 uM after 5 mins by fluorometric analysis	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID61808	Binding affinity towards human dopamine-4.2 receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID1054113	Binding affinity to adrenergic alpha1 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215951	Drug metabolism in human intestinal cytosol at 200 nM after 60 mins in presence of flufenamic acid	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID669781	Inhibition of human recombinant MDR1 expressed in mouse L5178Y cells assessed as inhibition of rhodamine-123 efflux at 10'-4 M preincubated for 10 mins measured after 20 mins by FACS analysis	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1430534	Displacement of [3H]-Raclopride from D2L receptor (unknown origin)
AID63811	Displacement of [3H]NPA from rat brain Dopamine receptor D2	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID298485	Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID313957	Displacement of [3H]prazosin from rat adrenergic alpha1A receptor expressed in fibroblast cells	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	1-Aminoindanes as novel motif with potential atypical antipsychotic properties.
AID1054115	Binding affinity to 5HT6 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1215953	Drug metabolism in human intestinal cytosol at 200 nM after 60 mins in presence of ondansetron	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID254688	Inhibitory concentration against dopamine receptor D2	2005	Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21	Designed multiple ligands. An emerging drug discovery paradigm.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID222148	K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1	2002	Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18	Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID87242	Binding affinity towards human histamine H1 receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID1653807	Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 200 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215937	Unbound intrinsic clearance in human intestinal cytosol at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID598251	Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 after 20 mins by FACS analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID503306	Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID298494	Displacement of [3H]pyrilamine from histaminergic H1 receptor guinea pig cerebellum	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID298483	Displacement of [3H]LSD from 5HT2B receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1054117	Binding affinity to dopamine D3 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID598252	Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 at 0.1 mM after 20 mins by FACS analysis relative to 5 mM sodium orthovanadate	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID243151	Inhibitory concentration against potassium channel HERG	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID141174	Binding affinity towards human M1 receptor.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID1578087	Brain to plasma partition coefficient, Kp of the compound in rat	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
AID1393471	Reversal of PCP-induced cognitive impairment in ip dosed Sprague-Dawley rat assessed as reduction in time spent exploring novel object over familiar object pretreated for 60 mins followed by PCP addition by novel object recognition assay
AID408340	Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	Support vector machines classification of hERG liabilities based on atom types.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID576612	Inhibition of human ERG	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID176733	Dose (administered orally) inhibiting amphetamine-induced locomotor behavior in rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID342777	Binding affinity to human cloned dopamine D2 receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID342784	Binding affinity to human cloned 5HT2A receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID298487	Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1393470	Therapeutic index, ratio of MED for sedation in ip dosed Sprague-Dawley rat to MED for antipsychotic activity in ip dosed Sprague-Dawley rat assessed as reduction in PCP-induced hyper-locomotion
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID65121	Binding affinity towards human dopamine receptor D3	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID1520010	Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis
AID1393523	Toxicity in Sprague-Dawley rat assessed as induction of catalepsy at 30 mg/kg, ip measured every 30 mins up to 240 mins by bar test
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID5616	Binding affinity towards human 5-hydroxytryptamine 2C receptor	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID330538	Orexigenic activity in H1RKO mouse	2007	Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9	From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1393367	Displacement of [3H]-5-CT from human 5-HT7R expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method
AID298493	Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID243189	Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)	2005	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6	A two-state homology model of the hERG K+ channel: application to ligand binding.
AID1393364	Displacement of [3H]-ketanserin from human 5-HT2AR expressed in CHO-K1 cell membranes after 1.5 hrs by microbeta counting method
AID1850916	Inhibition of GOT1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 10-01, Volume: 73	The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
AID1506226	Binding affinity to 5-HT2A (unknown origin)
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID599883	Displacement of [3H]mesulergine from human 5HT2C receptor in human tsA201 cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
AID342775	Binding affinity to human cloned dopamine D1 receptor	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID714083	Decrease in 5-HIAA level in Sprague-Dawley rat striatum at 6.4 umol/kg, sc by HPLC analysis relative to saline-treated control	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID5197	Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID1393368	Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method
AID298481	Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID374353	Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID298479	Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID298482	Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
AID1393469	Toxicity in ip dosed Sprague-Dawley rat assessed as sedation pretreated for 60 mins followed by PCP addition measured for 30 mins starting 15 min after rat reintroduction to auto-tracks
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID36113	Binding affinity towards human alpha-1 adrenergic receptor	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	Selective optimization of side activities: another way for drug discovery.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID714093	Reduction in spontaneous locomotor activity in Sprague-Dawley rat at 6.4 umol/kg, sc measured after 15 to 60 mins relative to saline-treated control	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID342787	Binding affinity to human SERT	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID63070	Binding affinity towards human D2 dopamine receptor.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	Current and novel approaches to the drug treatment of schizophrenia.
AID705397	Antipsychotic activity in sc dosed rat assessed as decrease in amphetamine-induced spontaneous locomotor activity	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
AID5328	Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346893	Human 5-HT2C receptor (5-Hydroxytryptamine receptors)	2003	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3	H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID1259419	Human 5-HT2A receptor (5-Hydroxytryptamine receptors)	2009	Journal of psychopharmacology (Oxford, England), Jan, Volume: 23, Issue:1	Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
AID624223	Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A	2003	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3	H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID1346603	Human 5-ht1e receptor (5-Hydroxytryptamine receptors)	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID1259419	Human 5-HT2A receptor (5-Hydroxytryptamine receptors)	2003	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3	H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID1346528	Human 5-HT1D receptor (5-Hydroxytryptamine receptors)	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID624210	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID1345788	Human D2 receptor (Dopamine receptors)	1998	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Feb, Volume: 18, Issue:2	Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.
AID1346037	Human H1 receptor (Histamine receptors)	2003	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3	H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID1346037	Human H1 receptor (Histamine receptors)	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID1346893	Human 5-HT2C receptor (5-Hydroxytryptamine receptors)	2000	The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1	Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
AID624210	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A	1998	European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID624223	Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A	2002	European journal of pharmacology, Aug-16, Volume: 450, Issue:1	A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
AID624230	Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID1346893	Human 5-HT2C receptor (5-Hydroxytryptamine receptors)	2009	Journal of psychopharmacology (Oxford, England), Jan, Volume: 23, Issue:1	Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
AID1345615	Human 5-HT1A receptor (5-Hydroxytryptamine receptors)	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID624223	Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID1259419	Human 5-HT2A receptor (5-Hydroxytryptamine receptors)	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID1259419	Human 5-HT2A receptor (5-Hydroxytryptamine receptors)	2002	European journal of pharmacology, Aug-16, Volume: 450, Issue:1	A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	1996	Psychopharmacology, Mar, Volume: 124, Issue:1-2	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
AID1346944	Rat NET (Monoamine transporter subfamily)	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
AID1345291	Human 5-HT7 receptor (5-Hydroxytryptamine receptors)	2005	Psychopharmacology, May, Volume: 179, Issue:2	Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
AID1345615	Human 5-HT1A receptor (5-Hydroxytryptamine receptors)	1998	European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3	Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347088	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347087	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347081	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	30 (3.04)	18.2507
2000's	529 (53.54)	29.6817
2010's	379 (38.36)	24.3611
2020's	50 (5.06)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	254 (23.78%)	5.53%
Reviews	168 (15.73%)	6.00%
Case Studies	203 (19.01%)	4.05%
Observational	3 (0.28%)	0.25%
Other	440 (41.20%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (132)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study [NCT01157559]	Phase 4	27 participants (Actual)	Interventional		Completed
Ziprasidone in Pediatric Bipolar Disorder: a 6-week, Open-label Comparison of Rapid vs. Slow Dose Titration [NCT00622739]	Phase 4	28 participants (Actual)	Interventional	2007-02-28	Completed
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year [NCT02534363]	Phase 4	136 participants (Actual)	Interventional	2005-10-31	Completed
Four Week, Double Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) [NCT01117220]	Phase 3	0 participants (Actual)	Interventional	2010-06-30	Withdrawn
26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC) [NCT03768726]	Phase 3	23 participants (Actual)	Interventional	2018-12-21	Terminated(stopped due to Pfizer has decided to perform the pre-specified final analysis at the current enrollment using a re-estimation of the sample size.)
A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder [NCT01172652]	Phase 4	49 participants (Actual)	Interventional	2010-04-30	Completed
Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up [NCT02526030]	Phase 4	203 participants (Actual)	Interventional	2008-10-31	Completed
26 Week Open Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) [NCT01124877]	Phase 3	0 participants (Actual)	Interventional	2010-07-31	Withdrawn
Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder [NCT01198353]	Phase 4	67 participants (Actual)	Interventional	2010-09-30	Completed
An Observational Drug Utilization Study of SYCREST^® (Asenapine) in the United Kingdom [NCT01498770]		42 participants (Actual)	Observational	2013-04-01	Completed
Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) [NCT00257166]	Phase 3	238 participants (Actual)	Interventional	2006-01-31	Completed
Outcomes of Antipsychotic Medication Use in the Emergency Department: A Retrospective Comparison Study [NCT02504450]		93 participants (Actual)	Observational	2015-04-30	Completed
A Randomized, Multi-site, Parallel-group, Rater-blind Study Comparing Response With Aripiprazole Once Monthly and Standard of Care Oral Antipsychotics in Non-adherent Outpatients With Schizophrenia Identified Using the Brief Adherence Rating Scale [NCT02282085]	Phase 4	200 participants (Anticipated)	Interventional	2014-12-31	Recruiting
An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression [NCT00835107]	Phase 4	14 participants (Actual)	Interventional	2009-02-28	Completed
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial [NCT02307396]	Phase 4	21 participants (Actual)	Interventional	2015-02-01	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fasting Conditions. [NCT01581866]	Phase 1	56 participants (Actual)	Interventional	2004-11-30	Completed
Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia [NCT00257192]	Phase 3	284 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to Please see Detailed Description for termination reason.)
Open Extension Study Evaluating the Safety and Tolerability of Oral Ziprasidone in the Treatment of Subjects Who Have Successfully Completed a Previous Ziprasidone Study [NCT00139737]	Phase 3	344 participants (Actual)	Interventional	2002-03-31	Completed
Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study [NCT01185743]	Phase 4	16 participants (Actual)	Interventional	2010-07-31	Completed
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia [NCT03781115]	Phase 1	24 participants (Anticipated)	Interventional	2017-11-20	Recruiting
An Open Label, Extension Study To Assess The Efficacy And Tolerability Of Oral Ziprasidone In Patients Successfully Completing A Previous Study With Ziprasidone [NCT00645320]	Phase 4	75 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers [NCT00910988]		46 participants (Actual)	Interventional	2009-02-28	Completed
Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study [NCT02192723]		550 participants (Actual)	Interventional	2012-06-30	Completed
Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia [NCT00509067]	Phase 2	43 participants (Actual)	Interventional	2007-11-30	Completed
High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms [NCT00403546]	Phase 3	131 participants (Actual)	Interventional	2006-01-31	Completed
Evaluation of Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotic Medications [NCT00458211]	Phase 4	40 participants (Actual)	Interventional	2005-05-31	Completed
26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia [NCT00265382]	Phase 3	221 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Please see Detailed Description for termination reason.)
A Six Week, Multicenter, Double Blind, Double-Dummy, Parallel, Comparative Study To Compare The Efficacy, Safety And Tolerability Of Ziprasidone With Risperidone In The Treatment Of Chinese Subjects With Acute Exacerbation Of Schizophrenia [NCT00645372]	Phase 3	242 participants (Actual)	Interventional	2004-07-31	Completed
A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder [NCT00649064]	Phase 4	46 participants (Actual)	Interventional	2003-12-31	Completed
Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone) [NCT00579670]		450 participants (Actual)	Observational	2007-10-31	Completed
Double Blind, Double-Dummy Multicenter, Parallel Group Comparison Of The Efficacy And The Tolerability Of Ziprasidone Vs. Clozapine In Schizophrenic Patients Who Are Refractory And/Or Intolerant To Antipsychotic Therapy [NCT00649844]	Phase 3	147 participants (Actual)	Interventional	2003-01-31	Completed
Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study [NCT00635921]	Phase 2	60 participants (Actual)	Interventional	2004-03-31	Completed
Double-blind, Placebo-controlled Trial of Ziprasidone (Geodon) for the Depressive Mixed State [NCT00490542]	Phase 2	73 participants (Actual)	Interventional	2006-12-31	Completed
A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression [NCT00483548]	Phase 3	298 participants (Actual)	Interventional	2007-10-31	Completed
26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) [NCT00265330]	Phase 3	169 participants (Actual)	Interventional	2006-03-31	Completed
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication [NCT03557931]	Phase 2	233 participants (Actual)	Interventional	2018-07-13	Completed
Ziprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study [NCT00645515]	Phase 3	240 participants (Anticipated)	Interventional	2003-06-30	Terminated(stopped due to This study was terminated on November 20, 2003 because of poor recruitment. This study was not terminated due to safety/efficacy.)
Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study [NCT00650429]	Phase 4	28 participants (Actual)	Interventional	2003-10-31	Completed
A One-Year, Phase IV, Open-Label, Non-Comparative Trial Of The Effect Of Ziprasidone HCL On Metabolic Syndrome Risk Factors In Patients With Psychotic Disorders [NCT00748566]	Phase 4	172 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to See Detailed Description)
A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia [NCT00723606]	Phase 3	376 participants (Actual)	Interventional	2008-09-30	Completed
Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data [NCT02582736]		725,489 participants (Actual)	Observational	2012-04-30	Completed
Efficacy And Safety Of Ziprasidone In Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder, Including Patients With A Diagnosis Of Recent Onset [NCT00645229]	Phase 3	1 participants (Actual)	Interventional	2004-09-30	Terminated(stopped due to Please see Detailed Description for termination reason.)
A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder [NCT00406315]	Phase 4	255 participants (Actual)	Interventional	2006-11-30	Completed
MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction [NCT01211522]	Phase 3	566 participants (Actual)	Interventional	2011-12-14	Completed
Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial [NCT00676429]	Phase 2	51 participants (Actual)	Interventional	2006-07-31	Completed
A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care [NCT00634348]	Phase 4	256 participants (Actual)	Interventional	2004-04-30	Completed
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders [NCT01006551]	Phase 2	40 participants (Actual)	Interventional	2002-12-31	Completed
A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients With Bipolar I Depression [NCT00141271]	Phase 3	536 participants (Actual)	Interventional	2005-07-31	Completed
Prospective Double Blind Randomized Trial of Intramuscular Ziprasidone Compared With Standard Antipsychotic Therapy For The Treatment Of The Acutely Agitated Patient In The Emergency Department [NCT00786318]	Phase 4	0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to Sponsor terminated)
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting. [NCT00932529]	Phase 4	226 participants (Actual)	Interventional	2003-02-28	Completed
A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic [NCT02600741]		296 participants (Actual)	Observational	2015-07-24	Completed
Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia [NCT02040883]	Phase 4	100 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD) [NCT00229385]		45 participants (Actual)	Interventional	2006-01-31	Completed
Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk [NCT00635700]	Phase 2	51 participants (Actual)	Interventional	2008-03-31	Completed
Phase 1 Study Of Ziprasidone Pharmacokinetics Of Reduced Food Effect Formulation B16 Under Fed And Fasting Conditions Compared To Commercial Geodon Capsules Under Fed Conditions In Healthy Subjects [NCT00821444]	Phase 1	11 participants (Actual)	Interventional	2009-01-31	Completed
The Metabolic Syndrome in Patients With Schizophrenia [NCT00338949]	Phase 4	77 participants (Actual)	Interventional	2006-06-30	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fed Conditions. [NCT01581879]	Phase 1	38 participants (Actual)	Interventional	2004-11-30	Completed
Open Extension Study Evaluating The Long Term Efficacy , Safety And Tolerability Of Oral Ziprasidone In The Treatment Of Patients Who Have Successfully Completed The Previous Ziprasidone Study A1281031 [NCT00174447]	Phase 3	43 participants (Actual)	Interventional	2001-10-31	Completed
A Multicenter, Randomized, Double-Blind, Parallel Group Study, Comparing The Efficacy And Tolerability Of Ziprasidone (Zeldox, Geodon) vs. Olanzapine (Zyprexa) In The Treatment And Maintenance Of Response In Patients With Acute Mania [NCT00329108]	Phase 4	29 participants (Actual)	Interventional	2006-11-30	Terminated(stopped due to Please see Brief Summary for Termination Reason.)
A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of [NCT00280566]	Phase 3	584 participants (Actual)	Interventional	2005-12-31	Completed
A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex [NCT00312494]	Phase 3	680 participants (Actual)	Interventional	2006-04-30	Completed
A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression [NCT00282464]	Phase 3	392 participants (Actual)	Interventional	2006-02-28	Completed
Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase [NCT01893229]	Phase 4	120 participants (Anticipated)	Interventional	2013-09-30	Recruiting
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Versus Non-Clozapine Antipsychotics in Individuals With Treatment-resistant Schizophrenia [NCT05741502]	Phase 4	60 participants (Anticipated)	Interventional	2023-08-16	Recruiting
Ziprasidone in Children With Autism: A Pilot Study [NCT00208559]	Phase 2	15 participants (Actual)	Interventional	2002-02-28	Completed
Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study. [NCT00239109]	Phase 4	112 participants	Interventional	2003-04-30	Completed
Reducing the Abuse Liability of Prescription Opioids [NCT04587115]	Early Phase 1	15 participants (Actual)	Interventional	2017-06-16	Completed
Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial [NCT00224315]	Phase 4	24 participants	Interventional	2003-11-30	Completed
Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder [NCT00472641]	Phase 4	25 participants (Actual)	Interventional	2007-01-31	Completed
A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral A [NCT00177164]	Phase 3	50 participants (Actual)	Interventional	2003-11-30	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar Disorder [NCT01113541]	Phase 3	13 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to See termination reason in detailed description.)
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study [NCT00818298]		12 participants (Actual)	Interventional	2009-01-31	Completed
A 27-Week Open-Label Trial To Characterize The Safety And Tolerability Of Orally Administered Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed), Schizophrenia Or Schizoaffective Disorder [NCT00650611]	Phase 2	63 participants (Actual)	Interventional	2003-12-31	Completed
An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis [NCT00644800]	Phase 4	89 participants (Actual)	Interventional	2003-07-31	Completed
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment [NCT02650102]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Post-Marketing Surveillance (PMS) Study to Evaluate Safety and Efficacy of Zeldox Capsule [NCT01053429]		3,391 participants (Actual)	Observational	2005-06-30	Completed
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia [NCT04076371]		1,640 participants (Actual)	Interventional	2012-01-31	Completed
Glucose Regulation During Ziprasidone Treatment [NCT00205725]		120 participants (Actual)	Interventional	2000-11-30	Completed
Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder [NCT00181922]	Phase 4	20 participants	Interventional	2002-03-31	Completed
Treatment Of Manic Or Mixed Episodes Of Up To Moderate Severity In Patients With Bipolar Disorder And Schizoaffective Disorder [NCT00454883]		379 participants (Actual)	Observational	2007-04-30	Completed
A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation [NCT02935998]	Phase 4	1,000 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]		3,520 participants (Actual)	Observational	2011-11-30	Completed
Safety and Efficacy of Four Intramuscular Interventions for the Management of Acute Psychomotor Agitation [NCT01485692]		120 participants (Actual)	Interventional	2009-02-28	Completed
An International, Multicenter, Large Simple Trial (LST) To Compare The Cardiovascular Safety Of Ziprasidone And Olanzapine [NCT00418171]	Phase 4	18,239 participants (Actual)	Interventional	2002-02-28	Completed
A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder [NCT00347425]	Phase 3	286 participants (Actual)	Interventional	2006-12-31	Completed
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone [NCT00096863]	Phase 2	102 participants (Actual)	Interventional	2004-12-31	Completed
An Open Trial to Evaluate the Efficacy and Tolerability of Ziprasidone IM and Oral in Patients With Psychosis and Acute Agitation. [NCT00136994]	Phase 3	160 participants	Interventional	2003-03-31	Completed
Open Extension Study Evaluating the Long-term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study [NCT00143351]	Phase 3	75 participants	Interventional	2003-06-30	Completed
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder : A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial [NCT01168674]	Phase 4	49 participants (Actual)	Interventional	2010-02-28	Completed
Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - [NCT00159770]	Phase 3	290 participants	Interventional	2001-11-30	Completed
Geodon (Ziprasidone) for Posttraumatic Stress Disorder [NCT00208208]	Phase 4	80 participants	Interventional	2002-12-31	Completed
Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder [NCT00374543]	Phase 4	3 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Recruitment goal could not be achieved)
Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial) [NCT00014001]	Phase 4	1,600 participants	Interventional	2000-12-31	Completed
A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression [NCT00034801]	Phase 4	378 participants	Interventional	2001-09-30	Completed
Treatment and Outcome of Early Onset Bipolar Disorder [NCT00048802]	Phase 4	40 participants	Interventional	2002-08-31	Completed
A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder [NCT00137020]	Phase 4	294 participants	Interventional	2004-11-30	Completed
Ziprasidone for the Treatment of Refractory Social Anxiety Disorder [NCT00215150]	Phase 2	51 participants (Actual)	Interventional	2004-11-30	Completed
The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder [NCT00395031]	Phase 2/Phase 3	57 participants (Actual)	Interventional	2003-09-30	Completed
PHARMACOLOGICAL TREATMENT OF COGNITIVE DEFICITS IN SCHIZOPHRENIC PATIENTS: The Effects of Central Cholinergic Augmentation on Cognitive Deficits and Psychopathology [NCT00206947]	Phase 2	50 participants (Anticipated)	Interventional	2002-12-31	Terminated(stopped due to No more funding)
A Multicenter, Double-Blind, Randomized Trial Of Ziprasidone (80 - 160 Mg) Versus Olanzapine (10 - 20 Mg) In Patients With Recent-Onset Schizophrenia, Schizoaffective And Schizophreniform Disorder. [NCT00145444]	Phase 3	100 participants	Interventional	2003-03-31	Completed
Energy Homeostasis and Metabolism in Patients With Schizophrenic Disorders Under Treatment With Atypical Antipsychotics [NCT00148564]	Phase 4	40 participants (Actual)	Interventional	2004-03-31	Completed
12 Week Open Label, Multicenter, Non-Comparative Switch Study Evaluating Efficacy, Tolerability And Safety Of Oral Ziprasidone In Treatment Of Patients Suffering From Schizophrenia Who Have Already Been Treated With An Other Antipsychotic. [NCT00159757]	Phase 4	150 participants	Interventional	2003-11-30	Terminated(stopped due to See Detailed Description for Termination Reason)
Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE) [NCT00330863]	Phase 4	357 participants (Actual)	Interventional	2006-05-31	Completed
A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol [NCT00340379]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2003-04-30	Completed
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder [NCT00555997]	Phase 2	120 participants (Actual)	Interventional	2008-03-31	Completed
Glucose and Lipid Metabolism on Antipsychotic Medication [NCT00515723]		96 participants (Actual)	Interventional	2001-09-30	Completed
Prospective Observational Investigation of Olanzapine Versus Haloperidol Versus Ziprasidone Versus Midazolam for the Treatment of Acute Undifferentiated Agitation in the Emergency Department [NCT03211897]		737 participants (Actual)	Observational	2017-06-15	Completed
A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness [NCT00199940]	Phase 4	20 participants	Interventional	2003-12-31	Completed
Effects of Ziprasidone vs. Placebo During the First Four Weeks of Eight Weeks Sertraline Treatment in Patients With Post-traumatic Stress Disorder (PTSD) [NCT00248261]		7 participants (Actual)	Observational	2005-11-30	Terminated(stopped due to High rate of early drop-outs)
Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle [NCT00297960]	Phase 4	0 participants	Interventional	2005-04-30	Completed
Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes [NCT00288353]	Phase 3	250 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to unable to secure additional funding)
[NCT03007303]		30 participants (Anticipated)	Observational [Patient Registry]	2016-06-30	Recruiting
Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. [NCT01714011]	Phase 4	175 participants (Actual)	Interventional	2009-05-31	Completed
Randomized Multicentric Open-label Phase III Clinical Trial to Evaluate the Efficacy of Continual Treatment Versus Discontinuation Based in the Presence of Prodromes in a First Episode of Non-affective Psychosis. [NCT01765829]	Phase 3	104 participants (Anticipated)	Interventional	2012-11-30	Recruiting
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building [NCT04446234]	Phase 4	350 participants (Anticipated)	Interventional	2021-05-31	Not yet recruiting
Reducing the Abuse Liability of Prescription Opioids in Recreational Drug Users: A Pilot Study [NCT03837860]	Early Phase 1	3 participants (Actual)	Interventional	2019-04-01	Terminated(stopped due to PI leaving institution)
Open-label Feasibility Study for the Treatment of Psychotic Adolescents With Ziprasidone in the Inpatient and Day Hospital Settings [NCT00421954]	Phase 3	8 participants (Actual)	Interventional	2006-05-31	Completed
Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder [NCT01293825]	Phase 4	30 participants (Actual)	Interventional	2011-01-31	Completed
Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade [NCT00225498]		35 participants (Actual)	Interventional	2002-06-30	Completed
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome [NCT00288366]		49 participants (Actual)	Interventional	2006-01-31	Completed
An Open-Label, Flexible-Dose Trial of the Safety and Efficacy of Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression [NCT00237666]	Phase 4	30 participants (Actual)	Interventional	2005-02-28	Completed
An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia [NCT00351000]	Phase 4	24 participants (Actual)	Interventional	2005-01-31	Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatmen [NCT00633399]	Phase 2	458 participants (Actual)	Interventional	2008-07-31	Completed
Gene-by-Stress Interactions in Intervention Studies Significance [NCT03011645]	Phase 1	7 participants (Actual)	Interventional	2018-05-24	Terminated(stopped due to Lack of participants)
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone [NCT00538642]		24 participants (Actual)	Interventional	2007-08-31	Completed
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain [NCT01844700]	Phase 4	14 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to very slow recruitment, no sufficient results)
Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT) [NCT00806234]	Phase 4	127 participants (Actual)	Interventional	2009-01-31	Completed
Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II) [NCT02305823]	Phase 4	203 participants (Actual)	Interventional	2005-10-31	Completed
A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (CURRENT OR MOST RECENT EPISODE MANIC) [NCT02075047]	Phase 3	171 participants (Actual)	Interventional	2014-05-23	Terminated(stopped due to Based on recent input from FDA, the pre-specified final analysis will be performed at the current enrollment using a re-estimation of the sample size.)
Effectiveness of Switching Antipsychotic Medications [NCT00044655]	Phase 4	219 participants (Actual)	Interventional	2001-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00044655 (1) [back to overview]	Number Who Discontinued Medication Within First 6 Study Months
NCT00139737 (1) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00141271 (38) [back to overview]	Change in Hamilton Depression (HAM-D 17) Total Score
NCT00141271 (38) [back to overview]	Change in Hamilton Anxiety Rating (HAM-A)
NCT00141271 (38) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score
NCT00141271 (38) [back to overview]	Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7
NCT00141271 (38) [back to overview]	Change in Total Score of Young Mania Rating Scale (YMRS)
NCT00141271 (38) [back to overview]	Change in Sleep Disturbance Factor Score
NCT00141271 (38) [back to overview]	Change in Tower of London Test at Endpoint
NCT00141271 (38) [back to overview]	Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF)
NCT00141271 (38) [back to overview]	Change in Assessment of Global Clinical Severity of Symptoms (CGI-S)
NCT00141271 (38) [back to overview]	Change in Global Clinical Improvement of Symptoms (CGI -I)
NCT00141271 (38) [back to overview]	Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Token Motor Task at Endpoint
NCT00141271 (38) [back to overview]	Change in Retardation Factor Scores
NCT00141271 (38) [back to overview]	Change in Verbal Fluency Controlled Word Association at Endpoint
NCT00141271 (38) [back to overview]	Change in Verbal Fluency in Naming Categories at Endpoint
NCT00141271 (38) [back to overview]	Change in Bech Melancholia Score
NCT00141271 (38) [back to overview]	Change in Verbal Memory Trial Performance Total Score at Endpoint
NCT00141271 (38) [back to overview]	Change in Anxiety/Somatizations Factor Total Score
NCT00141271 (38) [back to overview]	Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Digit Sequencing Task at Endpoint
NCT00141271 (38) [back to overview]	Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint
NCT00141271 (38) [back to overview]	Change in Sheehan Disability Scale (SDS) Total Score at Endpoint
NCT00141271 (38) [back to overview]	Change in Symbol Coding at Endpoint
NCT00141271 (38) [back to overview]	Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint
NCT00141271 (38) [back to overview]	Change in Total Score in Hamilton Depression (HAM-D 25)
NCT00141271 (38) [back to overview]	Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12
NCT00141271 (38) [back to overview]	Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score
NCT00141271 (38) [back to overview]	Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score
NCT00141271 (38) [back to overview]	Response as Measured by CGI-I Score Less Than or Equal to 2
NCT00174447 (6) [back to overview]	Change From Baseline in CGI-S at End of Study (up to 5 Years)
NCT00174447 (6) [back to overview]	Change From Baseline in CGI-I at End of Study (up to 5 Years)
NCT00174447 (6) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)
NCT00174447 (6) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)
NCT00174447 (6) [back to overview]	Number of Participants With Scores on Patient Preference Scale (PPS)
NCT00174447 (6) [back to overview]	Change From Baseline in Drug Attitude Inventory (DAI) at End of Study (up to 5 Years)
NCT00177164 (4) [back to overview]	BMI
NCT00177164 (4) [back to overview]	Number of Participants With Treatment Emergent Hyperlipidemia
NCT00177164 (4) [back to overview]	Number of Participants With Treatment - Emergent Hyperglycemia
NCT00177164 (4) [back to overview]	Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive Either Risperidal Consta or One of the 4 Marketed 2nd Generation Antipsychotic Agents.
NCT00215150 (1) [back to overview]	Brief Social Phobia Scale(BSPS)
NCT00225498 (1) [back to overview]	Working Memory
NCT00237666 (7) [back to overview]	Mean Change From Baseline in the Total Score of the Beck Depression Inventory (BDI)
NCT00237666 (7) [back to overview]	Mean Change From Baseline in the CGI-Severity of Illness (CGI-S) Score at Study Endpoint
NCT00237666 (7) [back to overview]	Mean Change From Baseline in the Hamilton Anxiety Scale (HAM-A)
NCT00237666 (7) [back to overview]	Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale
NCT00237666 (7) [back to overview]	Mean Change From Baseline in the Total Score of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
NCT00237666 (7) [back to overview]	The Primary Efficacy Endpoint is the Comparison of Baseline and Week 8 Endpoint in the 17-item HAM-D Total Scores
NCT00237666 (7) [back to overview]	Percentage of Subjects With Clinical Global Inventory (CGI) Global Improvement Score of 1 or 2
NCT00257166 (4) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 1, 2, 3 and 4
NCT00257166 (4) [back to overview]	Change From Baseline in Young Mania Rating Scale (YMRS) Score at Week 1, 2 and 3
NCT00257166 (4) [back to overview]	Change From Baseline in Young Mania Rating Scale (YMRS) Score at Week 4
NCT00257166 (4) [back to overview]	Clinical Global Impression - Improvement (CGI-I) Score
NCT00257192 (19) [back to overview]	Change From Baseline in Movement Disorder Scales: Barnes Akathisia Rating Scale (BAS) Global Clinical Assessment Item
NCT00257192 (19) [back to overview]	Change From Baseline in Child Depression Rating Scale - Revised (CDRS-R): Total Score
NCT00257192 (19) [back to overview]	Clinical Global Impression of Improvement (CGI-I) Score at Week 6
NCT00257192 (19) [back to overview]	Change From Baseline in Child Depression Rating Scale - Revised (CDRS-R): Suicide Ideation Item 13
NCT00257192 (19) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 6
NCT00257192 (19) [back to overview]	Change From Baseline in Child Depression Rating Scale - Revised (CDRS-R): Impaired Schoolwork Item 1
NCT00257192 (19) [back to overview]	Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total Score at Week 6
NCT00257192 (19) [back to overview]	Number of Subjects Per Response on the School Placement Questionnaire: School Situation
NCT00257192 (19) [back to overview]	Number of Subjects Per Response on the School Placement Questionnaire: School Attendance
NCT00257192 (19) [back to overview]	Number of Subjects Per Response on the School Placement Questionnaire: Overall School Performance
NCT00257192 (19) [back to overview]	Change From Baseline in PANSS: Positive and Negative Subscales at Week 6
NCT00257192 (19) [back to overview]	Change From Baseline in Movement Disorder Scales: Simpson-Angus Rating Scale (SARS)
NCT00257192 (19) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 6
NCT00257192 (19) [back to overview]	Change From Baseline in Movement Disorder Scales: Abnormal Involuntary Movement Scale (AIMS) Movement Cluster Score
NCT00257192 (19) [back to overview]	Change From Baseline in CNS Vital Signs Cognitive Test Battery: Neurocognitive Index
NCT00257192 (19) [back to overview]	Change From Baseline in CNS Vital Signs Cognitive Test Battery (Includes Sedation Item): Subscales
NCT00257192 (19) [back to overview]	Change From Baseline in Children's Problem Behavior and Aggression Questionnaire (CPBAQ) Total Score
NCT00257192 (19) [back to overview]	Change From Baseline in Children's Global Assessment Scale (CGAS)
NCT00257192 (19) [back to overview]	Change From Baseline in Child Health Questionnaire (CHQ)
NCT00265330 (19) [back to overview]	Body Mass Index (BMI) Z-score Frequency
NCT00265330 (19) [back to overview]	Young Mania Rating Scale (YMRS) Total Score Change From Baseline
NCT00265330 (19) [back to overview]	Mean Change From Baseline for Body Weight
NCT00265330 (19) [back to overview]	Body Mass Index (BMI) Z-score Frequency
NCT00265330 (19) [back to overview]	Frequency of Largest Categorical Increases in QTcF for Males
NCT00265330 (19) [back to overview]	Change in Hormones
NCT00265330 (19) [back to overview]	Change in Low-Density Lipoprotein (LDL) Cholesterol and Fasting Cholesterol
NCT00265330 (19) [back to overview]	Clinical Global Impression of Severity (CGI-S) Change From Baseline
NCT00265330 (19) [back to overview]	Frequency of Largest Categorical Increases in QTcF - All Subjects
NCT00265330 (19) [back to overview]	Frequency of Largest Categorical Increases in QTcF for Females
NCT00265330 (19) [back to overview]	Mean Change From Baseline in Supine Diastolic Blood Pressure
NCT00265330 (19) [back to overview]	Incidence of Lab Abnormalities
NCT00265330 (19) [back to overview]	Mean Change From Baseline for Body Mass Index (BMI) Z-Score
NCT00265330 (19) [back to overview]	Mean Change From Baseline for QTcF Intervals
NCT00265330 (19) [back to overview]	Mean Change From Baseline in Standing Diastolic Blood Pressure
NCT00265330 (19) [back to overview]	Mean Change From Baseline in Standing Pulse Rates
NCT00265330 (19) [back to overview]	Mean Change From Baseline in Standing Systolic Blood Pressure
NCT00265330 (19) [back to overview]	Mean Change From Baseline in Supine Pulse Rates
NCT00265330 (19) [back to overview]	Mean Change From Baseline in Supine Systolic Blood Pressure
NCT00265382 (15) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Cluster Score
NCT00265382 (15) [back to overview]	Change From Baseline in Children's Problem Behavior and Aggression Questionnaire (CPBAQ) Total Score
NCT00265382 (15) [back to overview]	Change From Baseline in Children's Global Assessment Scale (CGAS)
NCT00265382 (15) [back to overview]	Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00265382 (15) [back to overview]	Change From Baseline in CNS Vital Signs Cognitive Test Battery (Includes Sedation Item): Subscales
NCT00265382 (15) [back to overview]	Change From Baseline in Child Health Questionnaire (CHQ)
NCT00265382 (15) [back to overview]	Change From Baseline in Child Depression Rating Scale - Revised (CDRS-R): Total Score
NCT00265382 (15) [back to overview]	Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total Score
NCT00265382 (15) [back to overview]	Change From Baseline in Barnes Akathisia Rating Scale (BAS) Global Clinical Assessment Item
NCT00265382 (15) [back to overview]	Number of Subjects With Change From Baseline to Each Pubertal Stage of Development as Assessed by the Tanner Adolescent Pubertal Self Assessment
NCT00265382 (15) [back to overview]	Number of Subjects Per Response on the School Placement Questionnaire: School Situation
NCT00265382 (15) [back to overview]	Number of Subjects Per Response on the School Placement Questionnaire: School Attendance
NCT00265382 (15) [back to overview]	Change From Baseline in Simpson-Angus Rating Scale (SARS)
NCT00265382 (15) [back to overview]	Change From Baseline in CNS Vital Signs Cognitive Test Battery: Neurocognitive Index
NCT00265382 (15) [back to overview]	Number of Subjects Per Response on the School Placement Questionnaire: Overall School Performance
NCT00280566 (10) [back to overview]	Change From Baseline in Mania Rating Scale (MRS) by Visit During Double Blind Period
NCT00280566 (10) [back to overview]	Change From Baseline in Clinical Global Impression Severity (CGI-S) Score by Visit During Double Blind Period
NCT00280566 (10) [back to overview]	Time to Intervention for a Mood Episode During Double Blind Period
NCT00280566 (10) [back to overview]	Modified Time to Intervention for a Mood Episode (TIME)
NCT00280566 (10) [back to overview]	Time to Discontinuation for Any Reason During Double Blind Period 2
NCT00280566 (10) [back to overview]	Clinical Global Impression - Improvement (CGI-I) Score by Visit During Double Blind Period
NCT00280566 (10) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Visit During Double Blind Period
NCT00280566 (10) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Postive Scale by Visit During Double Blind Period
NCT00280566 (10) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Scale by Visit During Double Blind Period
NCT00280566 (10) [back to overview]	Change From Baseline in Montgomery-Asberg Rating Scale (MADRS) Score by Visit During Double Blind Period
NCT00282464 (22) [back to overview]	Change in Bipolar Cognition Rating Scale (BPCoRS) Subject Rating at Endpoint
NCT00282464 (22) [back to overview]	Change in Bipolar Cognition Rating Scale (BPCoRS) Interviewer Global Rating of Subject
NCT00282464 (22) [back to overview]	Change in Bipolar Cognition Rating Scale (BPCoRS) Informant Global Rating
NCT00282464 (22) [back to overview]	Change in Bipolar Cognition Rating Scale (BPCoRS) Global Rating by Interviewer
NCT00282464 (22) [back to overview]	Change in Hamilton Anxiety Rating (HAM-A)
NCT00282464 (22) [back to overview]	Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Rating Scale (MADRS) Total Score
NCT00282464 (22) [back to overview]	Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score
NCT00282464 (22) [back to overview]	Remission as Measured by Montgomery Asberg Depression Scale (MADRS) Total Score Less Than or Equal to 12
NCT00282464 (22) [back to overview]	Remission as Measured by Hamilton Asberg Depression Rating Scale (HAM-D 17) Total Score Less Than or Equal to 7
NCT00282464 (22) [back to overview]	Change in Total Score of Young Mania Rating Scale (YMRS)
NCT00282464 (22) [back to overview]	Change in Total Score in Hamiliton Depression Rating Scale (HAM-D 25)
NCT00282464 (22) [back to overview]	Change in Sleep Disturbance Factor Score
NCT00282464 (22) [back to overview]	Change in Retardation Factor Scores
NCT00282464 (22) [back to overview]	Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT00282464 (22) [back to overview]	Change in Hamilton Depression Rating Scale (HAM-D 17) Total Score
NCT00282464 (22) [back to overview]	Change in Global Clinical Severity of Symptoms (CGI-S)
NCT00282464 (22) [back to overview]	Change in Global Clinical Improvement of Symptoms (CGI -I)
NCT00282464 (22) [back to overview]	Change in Bech Melancholia Score
NCT00282464 (22) [back to overview]	Change in Anxiety/Somatizations Factor Total Score
NCT00282464 (22) [back to overview]	Change in Sheehan Disability Scale (SDS) Total Score
NCT00282464 (22) [back to overview]	Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score
NCT00282464 (22) [back to overview]	Change in Global Assessment of Functioning (GAF)
NCT00288366 (1) [back to overview]	HDL Ratio
NCT00312494 (8) [back to overview]	Change From Baseline in Global Assessment of Functioning (GAF) Score
NCT00312494 (8) [back to overview]	Change From Baseline in Clinical Global Impression Scale - Severity (CGI-S) Score
NCT00312494 (8) [back to overview]	Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Scores
NCT00312494 (8) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Score
NCT00312494 (8) [back to overview]	Change From Baseline to Week 1 and Week 2 in YMRS
NCT00312494 (8) [back to overview]	Clinical Global Impression - Improvement (CGI-I) Scale Scores
NCT00312494 (8) [back to overview]	Change From Baseline to Week 3 in Young Mania Rating Scale (YMRS)
NCT00312494 (8) [back to overview]	Change From Baseline in Longitudinal Interval Follow-up Evaluation Range of Impaired Functioning (LIFE-RIFT) Score
NCT00330863 (3) [back to overview]	Substantial Clinical Deterioration Measured by Psychotic Symptoms
NCT00330863 (3) [back to overview]	Number of Patients Discontinuing From the Study
NCT00330863 (3) [back to overview]	Side Effects and Metabolic Measures
NCT00338949 (2) [back to overview]	Change in Visceral Fat Mass From Baseline to Week 26
NCT00338949 (2) [back to overview]	Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min)
NCT00340379 (3) [back to overview]	21 Item Hamilton Depression Rating Scale
NCT00340379 (3) [back to overview]	Brief Psychiatric Rating Scale at 12 Weeks
NCT00340379 (3) [back to overview]	Clinical Global Impression Improvement Scale
NCT00351000 (2) [back to overview]	Change From Baseline on Fasting Insulin
NCT00351000 (2) [back to overview]	Change From Baseline in Fasting Glucose
NCT00403546 (17) [back to overview]	Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial
NCT00403546 (17) [back to overview]	Change From Baseline in Positive Subscale Score of PANSS
NCT00403546 (17) [back to overview]	Change From Baseline in the Calgary Depression Rating Scale (CDRS) Total Score
NCT00403546 (17) [back to overview]	Change From Baseline in the Barnes Akathisia Scale (BAS)
NCT00403546 (17) [back to overview]	Number of Participants With High and Low Levels in Serum Prolactin Concentration
NCT00403546 (17) [back to overview]	Number of Treatment-emergent Adverse Events During Randomized Trial
NCT00403546 (17) [back to overview]	Percentage of Participants With Response
NCT00403546 (17) [back to overview]	Vital Signs: Systolic and Diastolic Blood Pressure Levels
NCT00403546 (17) [back to overview]	Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS)
NCT00403546 (17) [back to overview]	Change in Schizophrenia Cognition Rating Scale (SCoRS) Score
NCT00403546 (17) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT00403546 (17) [back to overview]	Change From Baseline in PANSS Negative Subscale Score
NCT00403546 (17) [back to overview]	Change From Baseline in Global Assessment of Functioning (GAF) Score
NCT00403546 (17) [back to overview]	Change From Baseline in Clinical Global Impression- Severity (CGI-S) Score
NCT00403546 (17) [back to overview]	Change From Baseline in Clinical Global Impression - Improvement (CGI-I) Score
NCT00403546 (17) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score
NCT00403546 (17) [back to overview]	Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec)
NCT00406315 (15) [back to overview]	Change From Baseline in Weight at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Waist and Hip Circumference at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TQSM) Effectiveness, Side Effect, Convenience, and Global Satisfaction Subscales at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Schizophrenia Cognition Rating Scale (SCoRS) Total Score and Global Rating at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score, and Positive and Negative Subscale Scores at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Global Assessment of Function Scale (GAF) Score at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score, Global Severity Score, and Global Incapacitation Score at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Fasting Insulin at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Fasting Glucose at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), and Triglycerides at Week 16
NCT00406315 (15) [back to overview]	Observed Cases of Clinical Global Impression Improvement Scale (CGI-I) Scores at Week 16
NCT00406315 (15) [back to overview]	Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 16
NCT00458211 (15) [back to overview]	Clinical Global Impression (CGI) Scores the Evaluator's Overall Impression of Severity (CGI-S) or Change (CGI-I) in Illness.
NCT00458211 (15) [back to overview]	Cholesterol
NCT00458211 (15) [back to overview]	Calgary Depression Scale for Schizophrenia
NCT00458211 (15) [back to overview]	Fasting Glucose
NCT00458211 (15) [back to overview]	Insulin Level
NCT00458211 (15) [back to overview]	Medical Outcomes Study Cognitive Functioning Scale (MOS-COG)
NCT00458211 (15) [back to overview]	Brief Assessment of Cognition in Schizophrenia (BACS)
NCT00458211 (15) [back to overview]	Barnes Akathisia Scale
NCT00458211 (15) [back to overview]	Corrected QT Interval (QTc)
NCT00458211 (15) [back to overview]	Abnormal Involuntary Movement Scale (AIMS) Measures Tardive Dyskinesia
NCT00458211 (15) [back to overview]	Personal Evaluation of Transitions in Treatment Scale (PETiTP
NCT00458211 (15) [back to overview]	Positive and Negative Syndrome Scale (PANSS) Measuring Symptoms of Schizophrenia
NCT00458211 (15) [back to overview]	Simpson-Angus Scale Measures Drug Induced Parkinsonism
NCT00458211 (15) [back to overview]	HbA1c
NCT00458211 (15) [back to overview]	Weight
NCT00472641 (2) [back to overview]	The Primary Outcome Measure Was Weight Change From Baseline to Endpoint.
NCT00472641 (2) [back to overview]	Changes From Baseline to Endpoint in Body Mass Index (BMI)
NCT00483548 (17) [back to overview]	Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
NCT00483548 (17) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Week 6 (Items 4 and 5)
NCT00483548 (17) [back to overview]	Change From Baseline to Week 6 in Clinical Global Impression - Severity Scale (CGI-Severity or CGI-S)
NCT00483548 (17) [back to overview]	Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT00483548 (17) [back to overview]	Clinical Global Impression - Improvement Scale (CGI-Improvement or CGI-I): Number of Subjects With Response (Much Improved or Very Much Improved) at Week 6
NCT00483548 (17) [back to overview]	MADRS Remission: Number of Subjects With Total MADRS Score ≤ 12 at Week 6
NCT00483548 (17) [back to overview]	MADRS Response: Number of Subjects With Total MADRS Score Reduction ≥ 50 Percent From Baseline at Week 6
NCT00483548 (17) [back to overview]	CGI-Improvement Score
NCT00483548 (17) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Scores
NCT00483548 (17) [back to overview]	Change From Baseline in Barnes Akathisia Rating Scale (BARS or BAS)
NCT00483548 (17) [back to overview]	Change From Baseline in CGI-Severity Score (Post-baseline Excluding Week 6)
NCT00483548 (17) [back to overview]	Change From Baseline in Global Assessment of Functioning (GAF) Scale at Week 6
NCT00483548 (17) [back to overview]	Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score
NCT00483548 (17) [back to overview]	Change From Baseline in MADRS Total Score (Post-baseline Excluding Week 6)
NCT00483548 (17) [back to overview]	Change From Baseline in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Scores at Week 6
NCT00483548 (17) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) at Week 6 (Items 1 Through 3)
NCT00483548 (17) [back to overview]	Change From Baseline in Simpson Angus Scale (SAS) Score
NCT00490542 (1) [back to overview]	The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups.
NCT00509067 (3) [back to overview]	MATRICS Verbal Learning and Memory
NCT00509067 (3) [back to overview]	Clinical Global Impression
NCT00509067 (3) [back to overview]	Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)
NCT00515723 (2) [back to overview]	DEXA Total Fat
NCT00515723 (2) [back to overview]	Clamp Derived Insulin Sensitivity (mg/kg/Min)
NCT00538642 (18) [back to overview]	Insulin Sensitivity
NCT00538642 (18) [back to overview]	Triglycerides
NCT00538642 (18) [back to overview]	Systolic Blood Pressure
NCT00538642 (18) [back to overview]	Systolic Blood Pressure
NCT00538642 (18) [back to overview]	LDL Cholesterol
NCT00538642 (18) [back to overview]	LDL Cholesterol
NCT00538642 (18) [back to overview]	Insulin Sensitivity
NCT00538642 (18) [back to overview]	Cholesterol
NCT00538642 (18) [back to overview]	HDL Cholesterol
NCT00538642 (18) [back to overview]	HDL Cholesterol
NCT00538642 (18) [back to overview]	Diastolic Blood Pressure
NCT00538642 (18) [back to overview]	Cholesterol
NCT00538642 (18) [back to overview]	Body Mass Index
NCT00538642 (18) [back to overview]	Body Mass Index
NCT00538642 (18) [back to overview]	Abdominal Circumference
NCT00538642 (18) [back to overview]	Abdominal Circumference
NCT00538642 (18) [back to overview]	Triglycerides
NCT00538642 (18) [back to overview]	Diastolic Blood Pressure
NCT00555997 (2) [back to overview]	Hamilton Depression Rating Scale (HAM-D-17) Scores
NCT00555997 (2) [back to overview]	Responder/Non-responder
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question As a Result of Taking This Medication, do You Experience Any Side Effects at All?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question As a Result of Taking This Medication, do You Experience Any Side Effects at All?: Within SmPC"
NCT00579670 (45) [back to overview]	Percent Change From Baseline to Final Visit in Body Weight: Within SmPC
NCT00579670 (45) [back to overview]	Percent Change From Baseline to Final Visit in Body Weight
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?: Within SmPC"
NCT00579670 (45) [back to overview]	Summary of Schizophrenia
NCT00579670 (45) [back to overview]	Summary of Most Frequently Used Concomitant Drug Treatments
NCT00579670 (45) [back to overview]	Summary of Metabolic Risk Factors
NCT00579670 (45) [back to overview]	Positive and Negative Syndrome Scale (PANSS) - Positive Subscale: Within SmPC
NCT00579670 (45) [back to overview]	Positive and Negative Syndrome Scale (PANSS) - Positive Subscale
NCT00579670 (45) [back to overview]	PANSS - Negative Subscale: Within SmPC
NCT00579670 (45) [back to overview]	PANSS - Negative Subscale
NCT00579670 (45) [back to overview]	PANSS - Composite Subscale: Within SmPC
NCT00579670 (45) [back to overview]	PANSS - Composite Subscale
NCT00579670 (45) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S): Within SmPC
NCT00579670 (45) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)
NCT00579670 (45) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I): Within Summary of Product Characteristics Population (SmPC)
NCT00579670 (45) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)
NCT00579670 (45) [back to overview]	Number of Participants Continuing Treatment With Ziprasidone Following Completion of the Observation Period: Within SmPC
NCT00579670 (45) [back to overview]	Number of Participants Continuing Treatment With Ziprasidone Following Completion of the Observation Period
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question Overall, How Confident Are You That Taking This Medication is a Good Thing?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question Overall, How Confident Are You That Taking This Medication is a Good Thing?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Easy or Difficult is it to Use the Medication in Its Current Form?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Easy or Difficult is it to Use the Medication in Its Current Form?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Convenient or Inconvenient is it to Take the Medication as Instructed?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Convenient or Inconvenient is it to Take the Medication as Instructed?: Within SmPC"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?"
NCT00579670 (45) [back to overview]	"Number of Participants Answering the Question How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?: Within SmPC"
NCT00622739 (6) [back to overview]	Barnes Akathisia Rating Scale (BARS)
NCT00622739 (6) [back to overview]	Children's Depression Rating Scale
NCT00622739 (6) [back to overview]	Clinical Global Impressions-Severity (CGI-S) Scale
NCT00622739 (6) [back to overview]	SAFTEE (Side Effects Rating Scale)
NCT00622739 (6) [back to overview]	AIMS (Abnormal Involuntary Movement Scale)
NCT00622739 (6) [back to overview]	Young Mania Rating Scale (YMRS)
NCT00633399 (3) [back to overview]	Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.
NCT00633399 (3) [back to overview]	Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8
NCT00633399 (3) [back to overview]	The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2
NCT00635700 (2) [back to overview]	Change in Scale of Psychosis-risk Symptoms Total Score
NCT00635700 (2) [back to overview]	Conversion to Psychosis
NCT00723606 (6) [back to overview]	Clinical Global Impression-Improvement (CGI-I) Score at 72 Hours
NCT00723606 (6) [back to overview]	Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours
NCT00723606 (6) [back to overview]	Change From Baseline in BPRS Agitation Subscale Score at 72 Hours
NCT00723606 (6) [back to overview]	Change From Baseline in Behavioral Activity Rating Scale (BARS) at 72 Hours
NCT00723606 (6) [back to overview]	Change From Baseline in Clinical Global Impressions Severity (CGI-S) Score at 72 Hours
NCT00723606 (6) [back to overview]	BPRS Agitation Subscale Response at 72 Hours
NCT00748566 (24) [back to overview]	Change From Baseline in QT Interval Corrected for Heart Rate (QTc) at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Positive and Negative Subscale Scores at Week 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Insulin Level at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) Concentration at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Fasting Glucose Level at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in European Quality of Life (EuroQoL) - 5 Dimensions Index (EQ-I) Score at Week 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Drug-Attitude Inventory-30-Item Scale (DAI-30) Score at Week 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Week 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in 10-year Cardiovascular Heart Disease (CHD) Risk According to Framingham Scoring System at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Percentage of Participants Achieving at Least 1 Risk Factor Reduction From Baseline for Metabolic Syndrome (MS)
NCT00748566 (24) [back to overview]	Clinical Global Impression-Improvement (CGI-I) Scale Score
NCT00748566 (24) [back to overview]	Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Percentage of Participants With Metabolic Syndrome (MS)
NCT00748566 (24) [back to overview]	Percentage of Participants With Individual Risk Factors of Metabolic Syndrome (MS)
NCT00748566 (24) [back to overview]	Number of Participants With Change From Baseline in Metabolic Syndrome (MS) Risk Factors at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Mean Change From Baseline in the Number of Risk Factors of Metabolic Syndrome (MS) at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Changes From Baseline in European Quality of Life (EuroQoL) - 5 Dimensions Visual Analog Scale (VAS) Score at Week 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Weight at Week 4,12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Waist Circumference at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Triglyceride and High Density Lipoprotein-Cholesterol (HDL-C) Levels at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Total Cholesterol (TC) and Low Density Lipoprotein-Cholesterol (LDL-C) Levels at Week 4, 12, 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in Social and Occupational Functioning Assessment Scale (SOFAS) Score at Week 28 and 52
NCT00748566 (24) [back to overview]	Change From Baseline in the Physical Activity Index Score at Week 28 and 52
NCT00806234 (4) [back to overview]	Change in Whole Body Insulin Sensitivity Index
NCT00806234 (4) [back to overview]	Change in Low Density Lipoprotein (LDL) Cholesterol Level
NCT00806234 (4) [back to overview]	Body Mass Index (BMI) Z-score Change
NCT00806234 (4) [back to overview]	Triglyceride Levels
NCT00910988 (4) [back to overview]	Peripheral Insulin Sensitivity
NCT00910988 (4) [back to overview]	Whole Body Insulin Sensitivity
NCT00910988 (4) [back to overview]	Adipose Tissue Insulin Sensitivity
NCT00910988 (4) [back to overview]	Hepatic Insulin Sensitivity
NCT01053429 (4) [back to overview]	Number of Participants for Change From Baseline in Clinical Global Impression - Improvement (CGI-I) at Final Visit (up to Week 8) - ITT
NCT01053429 (4) [back to overview]	Number of Participants for Change From Baseline in Clinical Global Impression - Improvement (CGI-I) at Final Visit (up to Week 8) - PP
NCT01053429 (4) [back to overview]	Number of Participants for Clinical Global Impression of Severity (CGI-S) Status at Final Visit (up to Week 8) - Intent to Treat Population
NCT01053429 (4) [back to overview]	Number of Participants for Clinical Global Impression of Severity (CGI-S) Status at Final Visit (up to Week 8) - Per Protocol Population
NCT01113541 (5) [back to overview]	Change From Baseline in Total Cholesterol and Low-density Lipoprotein (LDL) Cholesterol Levels
NCT01113541 (5) [back to overview]	Change From Baseline in Weight
NCT01113541 (5) [back to overview]	Percentage of Participants Who Achieved a Reduction From Baseline of at Least 1 Risk Factor for Metabolic Syndrome (MS) at Week 52 or Premature Discontinuation
NCT01113541 (5) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c)
NCT01113541 (5) [back to overview]	Change From Baseline in Corrected QT Interval (QTc): Fridericia's Heart Rate Correction Formula (QTcF)
NCT01168674 (2) [back to overview]	MADRS Improvement Over 6 Weeks
NCT01168674 (2) [back to overview]	Predictors of Bipolarity to Define the Study Population
NCT01211522 (10) [back to overview]	Time to Hospital Discharge
NCT01211522 (10) [back to overview]	Time to ICU Readmission
NCT01211522 (10) [back to overview]	Time to Liberation From Mechanical Ventilation
NCT01211522 (10) [back to overview]	Delirium Duration
NCT01211522 (10) [back to overview]	Delirium/Coma-free Days (DCFDs)
NCT01211522 (10) [back to overview]	Number of Participants With Extrapyramidal Symptoms
NCT01211522 (10) [back to overview]	Number of Participants With Neuroleptic Malignant Syndrome
NCT01211522 (10) [back to overview]	Mortality
NCT01211522 (10) [back to overview]	Number of Participants With Torsades de Pointes
NCT01211522 (10) [back to overview]	Time to Final ICU Discharge
NCT01293825 (9) [back to overview]	Global Psychopathology Score as Measured by Clinical Global Impressions
NCT01293825 (9) [back to overview]	Montgomery Asberg Depression Rating Scale
NCT01293825 (9) [back to overview]	Social and Occupational Functioning Scale
NCT01293825 (9) [back to overview]	Treatment Adherence Score as Measured by the Morisky Rating Scale
NCT01293825 (9) [back to overview]	Young Mania Rating Scale
NCT01293825 (9) [back to overview]	Quality of Life Score as Measured by 12-item Short Form Health Survey
NCT01293825 (9) [back to overview]	Treatment Non-adherence Percentage as Measured by the Tablet Routines Questionnaire (TRQ)
NCT01293825 (9) [back to overview]	Body Weight
NCT01293825 (9) [back to overview]	Attitude Toward Medication Score as Measured by the Drug Attitude Inventory
NCT01844700 (4) [back to overview]	BMI Percentile
NCT01844700 (4) [back to overview]	BMI Z-scores
NCT01844700 (4) [back to overview]	Weight Change
NCT01844700 (4) [back to overview]	Percent Weight Change Compared to Baseline Weight
NCT02075047 (20) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02075047 (20) [back to overview]	Number of Participants Who Took at Least 1 Concomitant Medication and Concomitant Non-Drug Treatments/Procedures
NCT02075047 (20) [back to overview]	Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 1, 2, and 3
NCT02075047 (20) [back to overview]	Change From Baseline in Simpson-Angus Rating Scale (SARS) Total Score at Weeks 1, 2, 3, and 4
NCT02075047 (20) [back to overview]	Change From Baseline in Pulse Rate at Week 1, 2, 3, 4, Early Termination Visit and Follow-up Visit
NCT02075047 (20) [back to overview]	Clinical Global Impression of Improvement (CGI-I) Scores at Weeks 1, 2, 3, and 4
NCT02075047 (20) [back to overview]	Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) - Movement Cluster Score at Weeks 1, 2, 3, and 4
NCT02075047 (20) [back to overview]	Number of Participants With Physical Examination Abnormalities
NCT02075047 (20) [back to overview]	Number of Participants With Laboratory Abnormalities
NCT02075047 (20) [back to overview]	Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 4
NCT02075047 (20) [back to overview]	Change From Baseline in Height and Waist Circumference at Week 4 and Early Termination Visit
NCT02075047 (20) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Weeks 1, 2, 3, and 4
NCT02075047 (20) [back to overview]	Change From Baseline in Body Weight at Week 4 and Early Termination Visit
NCT02075047 (20) [back to overview]	Change From Baseline in Body Mass Index (BMI) Z-score at Week 4 and Early Termination Visit
NCT02075047 (20) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Week 4 and Early Termination Visit
NCT02075047 (20) [back to overview]	Change From Baseline in Blood Pressure at Week 1, 2, 3, 4, Early Termination Visit and Follow-up Visit
NCT02075047 (20) [back to overview]	Change From Baseline in Barnes Akathisia Rating Scale (BAS): Global Clinical Assessment of Akathisia Subscale Score at Weeks 1, 2, 3, and 4
NCT02075047 (20) [back to overview]	Number of Participants With Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categorization Mapped From Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT02075047 (20) [back to overview]	Number of Participants With Pre-defined Categories of Electrocardiogram (ECG) Findings
NCT02075047 (20) [back to overview]	Change From Baseline in Children's Depression Rating Scale (CDRS-R) Total Score at Weeks 1, 2, 3, and 4 and Early Termination Visit
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Barnes Akathisia Rating Scale (BARS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Adverse Event (AE)
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Abnormal Involuntary Movement Scale (AIMS) Values
NCT03557931 (8) [back to overview]	Concentration at Trough Level (Ctrough) for ASP4345
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Columbia-Suicide Severity Rating Scale (C-SSRS) Values
NCT03557931 (8) [back to overview]	Number of Participants With Clinically Significant Differences in Simpson Angus Scale (SAS) Values
NCT03557931 (8) [back to overview]	Change From Baseline to Week 12/EoT in University of California San Diego Performance-based Skills Assessment-2 Extended Range (UPSA-2-ER) Total Score
NCT03557931 (8) [back to overview]	Change From Baseline to Week 12/End of Treatment (EoT) in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score
NCT03768726 (19) [back to overview]	Number of Participants With Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categorization Mapped From Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT03768726 (19) [back to overview]	Change From Baseline in Body Weight at Week 6, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Body Mass Index (BMI) Z-score at Week 6, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Body Mass Index (BMI) at Week 6, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Blood Pressure at Week 1, 2, 4, 6, 10, 14, 18, 22, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Number of Participants With Laboratory Abnormalities
NCT03768726 (19) [back to overview]	Change From Baseline in Children's Global Assessment Scale (CGAS) Total Score at Week 26
NCT03768726 (19) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03768726 (19) [back to overview]	Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 1, 2, 4, 6, 10, 14, 18, 22, 26
NCT03768726 (19) [back to overview]	Change From Baseline in Electrocardiogram (ECG) Parameters at Day 1, Week 1, 2, 4, 6, 14, 22, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Children's Depression Rating Scale (CDRS-R) Total Score at Week 26
NCT03768726 (19) [back to overview]	Change From Baseline in Pulse Rate at Week 1, 2, 4, 6, 10, 14, 18, 22, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Height and Waist Circumference at Week 6, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Simpson-Angus Rating Scale (SARS) Total Score at Week 1, 2, 4, 6, 10, 14, 18, 22, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Heart Rate at Day 1, Week 1, 2, 4, 6, 14, 22, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Global Clinical Assessment of Akathisia Subscale Score of Barnes Akathisia Rating Scale (BAS) at Week 1, 2, 4, 6, 10, 14, 18, 22, 26 and Follow-up Visit
NCT03768726 (19) [back to overview]	Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 1, 2, 6, 14, 22, 26
NCT03768726 (19) [back to overview]	Number of Participants With Physical Examination Abnormalities at Baseline and Week 26
NCT03768726 (19) [back to overview]	Change From Baseline in Movement Cluster Subscale Score of Abnormal Involuntary Movement Scale (AIMS) at Week 1, 2, 4, 6, 10, 14, 18, 22, 26 and Follow-up Visit

Number Who Discontinued Medication Within First 6 Study Months

(NCT00044655)
Timeframe: Measured at Six Months

Intervention	participants (Number)
Stay	11
Switch	23

Intervention	score on scale (Least Squares Mean)
	Week 3 (n= 147, 149, 148)	Week 6 (n= 104,117,125)	Endpoint (n= 151,150,153)
120-160mg Ziprasidone	-9.56	-12.37	-10.48
40-80 mg Ziprasidone	-10.58	-12.82	-11.48
Placebo	-10.13	-11.30	-10.60

Intervention	score on scale (Least Squares Mean)
	Week 3 (n= 147, 148, 147)	Week 6 (n= 104, 117, 124)	Endpoint (n= 151, 150, 152)
120-160mg Ziprasidone	-5.54	-7.63	-6.40
40-80 mg Ziprasidone	-6.46	-7.46	-6.75
Placebo	-6.79	-6.73	-6.82

Intervention	score on scale (Least Squares Mean)
	Week 1 (n=161, 153, 159)	Week 2 (n=135, 142, 146)	Week 3 (n=120, 131, 138)	Week 4 (n=106, 126, 131)	Week 5 (n=99, 115, 123)	Week 6 (n=95, 107, 115)	Overall (n=166, 158, 162)
120-160mg Ziprasidone	-6.07	-10.12	-11.61	-12.54	-14.25	-13.81	-11.40
40-80 mg Ziprasidone	-7.66	-10.20	-12.93	-13.87	-14.53	-14.77	-12.33
Placebo	-5.75	-9.47	-11.37	-12.49	-12.99	-13.25	-10.89

Intervention	Participants (Number)
	Week 3; Yes	Week 3; No	Week 6; Yes	Week 6; No	Endpoint: Yes	Endpoint: No
120-160mg Ziprasidone	27	120	41	63	45	106
40-80 mg Ziprasidone	30	119	43	74	44	106
Placebo	35	113	43	82	47	106

Intervention	score on scale (Least Squares Mean)
	Week 1 (n = 140,131, 132)	Week 2 (n = 114,124,123)	Week 3 (n = 120, 130, 138)	Week 4 (n = 93, 116, 116)	Week 5 (n = 87, 105, 109)	Week 6 (n = 95, 107, 115)	Overall (n = 161, 158, 161)
120-160mg Ziprasidone	0.05	0.16	-0.03	-0.09	-0.89	-0.86	-0.27
40-80 mg Ziprasidone	0.64	0.64	0.11	0.19	-0.82	-0.03	0.12
Placebo	-0.08	0.51	0.05	-0.73	-0.28	-1.00	-0.26

Intervention	score on scale (Least Squares Mean)
	Week 3 (n = 147, 149, 148)	Week 6 (n = 104, 117, 125)	Endpoint (n = 151, 150 153)
120-160mg Ziprasidone	-1.92	-2.20	-1.90
40-80 mg Ziprasidone	-2.07	-2.19	-1.98
Placebo	-1.96	-2.06	-1.96

Intervention	score on scale (Least Squares Mean)
120-160mg Ziprasidone	10.11
40-80 mg Ziprasidone	11.72
Placebo	11.19

Intervention	score on scale (Least Squares Mean)
	Week 1 (n=161, 152, 158)	Week 2 (n=133, 142, 147)	Week 3 (n=119, 131, 137)	Week 4 (n=105, 126, 130)	Week 5 (n=98, 115, 123)	Week 6 (n=94, 107, 115)	Overall (n=165, 158, 162)
120-160mg Ziprasidone	-0.05	-0.84	-0.90	-1.14	-1.33	-1.38	-1.02
40-80 mg Ziprasidone	-0.47	-0.82	-1.15	-1.23	-1.35	-1.38	-1.07
Placebo	-0.42	-0.75	-0.93	-1.14	-1.23	-1.35	-0.97

Intervention	score on scale (Least Squares Mean)
	Week 1 (n=162, 152, 158)	Week 2 (n=134, 142, 147)	Week 3 (n=120,131,137)	Week 4 (n=106,126,130)	Week 5 (n=99, 115, 123)	Week 6 (n=95,107, 115)	Overall (n=166, 158, 162)
120-160mg Ziprasidone	3.34	2.86	2.90	2.54	2.47	2.49	2.77
40-80 mg Ziprasidone	3.17	2.82	2.62	2.53	2.48	2.43	2.67
Placebo	3.38	3.01	2.83	2.55	2.59	2.52	2.81

Intervention	Number of Tokens (Least Squares Mean)
120-160mg Ziprasidone	0.28
40-80 mg Ziprasidone	-0.00
Placebo	2.02

Intervention	score on scale (Least Squares Mean)
	Week 3 (n = 147,149,148)	Week 6 (n = 104,117,125)	Endpoint (n = 151,150,153)
120-160mg Ziprasidone	-3.50	-4.44	-3.89
40-80 mg Ziprasidone	-3.64	-4.40	-3.99
Placebo	-3.59	-3.79	-3.62

Intervention	Number Correct (Least Squares Mean)
120-160mg Ziprasidone	1.09
40-80 mg Ziprasidone	-0.15
Placebo	1.54

Intervention	score on scale (Least Squares Mean)
	Week 3 (n = 147, 149, 148)	Week 6 (n = 104, 117, 125)	Endpoint (n =151, 150, 153)
120-160mg Ziprasidone	-5.12	-6.91	-5.85
40-80 mg Ziprasidone	-5.61	-6.93	-6.23
Placebo	-5.22	-6.23	-5.70

Intervention	words (Least Squares Mean)
120-160mg Ziprasidone	-0.02
40-80 mg Ziprasidone	0.14
Placebo	-0.00

Intervention	Words (Least Squares Mean)
120-160mg Ziprasidone	-0.37
40-80 mg Ziprasidone	0.15
Placebo	0.23

Intervention	Number Correct (Least Squares Mean)
120-160mg Ziprasidone	0.09
40-80 mg Ziprasidone	0.01
Placebo	-0.03

Intervention	Number Correct (Least Squares Mean)
120-160mg Ziprasidone	-0.18
40-80 mg Ziprasidone	-0.24
Placebo	-0.02

Intervention	Number Correct (Least Squares Mean)
120-160mg Ziprasidone	0.06
40-80 mg Ziprasidone	0.19
Placebo	0.14

Intervention	words (Least Squares Mean)
120-160mg Ziprasidone	-0.06
40-80 mg Ziprasidone	-0.07
Placebo	0.08

Intervention	words (Least Squares Mean)
120-160mg Ziprasidone	-0.39
40-80 mg Ziprasidone	-0.01
Placebo	-0.32

ziprasidone

Description

Cross-References

Synonyms (86)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (6)

Drug Classes (4)

Protein Targets (83)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (552)

Molecular Functions (141)

Ceullar Components (95)

Bioassays (289)

Research

Studies (988)

Market Indicators

Research Demand Index: 93.42

Study Types

Clinical Trials (132)

Trial Overview

Trial Outcomes

Number Who Discontinued Medication Within First 6 Study Months

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Change in Hamilton Depression (HAM-D 17) Total Score

Change in Hamilton Anxiety Rating (HAM-A)

Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score

Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7

Change in Total Score of Young Mania Rating Scale (YMRS)

Change in Sleep Disturbance Factor Score

Change in Tower of London Test at Endpoint

Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF)

Change in Assessment of Global Clinical Severity of Symptoms (CGI-S)

Change in Global Clinical Improvement of Symptoms (CGI -I)

Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint

Change in Token Motor Task at Endpoint

Change in Retardation Factor Scores

Change in Verbal Fluency Controlled Word Association at Endpoint

Change in Verbal Fluency in Naming Categories at Endpoint

Change in Bech Melancholia Score

Change in Verbal Memory Trial Performance Total Score at Endpoint

Change in Anxiety/Somatizations Factor Total Score

Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint

Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint

Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint

Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint

Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint

Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint

Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint

Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint

Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint

Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint

Change in Digit Sequencing Task at Endpoint

Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint

Change in Sheehan Disability Scale (SDS) Total Score at Endpoint

Change in Symbol Coding at Endpoint

Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint

Change in Total Score in Hamilton Depression (HAM-D 25)

Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12

Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score

Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score

Response as Measured by CGI-I Score Less Than or Equal to 2

Change From Baseline in CGI-S at End of Study (up to 5 Years)

Change From Baseline in CGI-I at End of Study (up to 5 Years)

Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)

Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)

Number of Participants With Scores on Patient Preference Scale (PPS)

Change From Baseline in Drug Attitude Inventory (DAI) at End of Study (up to 5 Years)

BMI

Number of Participants With Treatment Emergent Hyperlipidemia

Intervention	words (Least Squares Mean)
120-160mg Ziprasidone	-0.52
40-80 mg Ziprasidone	-0.15
Placebo	-0.24

Intervention	Number Correct (Least Squares Mean)
120-160mg Ziprasidone	0.76
40-80 mg Ziprasidone	0.09
Placebo	0.46

Intervention	score on scale (Least Squares Mean)
120-160mg Ziprasidone	-5.78
40-80 mg Ziprasidone	-5.43
Placebo	-6.79

Intervention	words (Least Squares Mean)
120-160mg Ziprasidone	-0.16
40-80 mg Ziprasidone	0.07
Placebo	0.13

Intervention	score on scale (Least Squares Mean)
	Week 3 (n= 147, 149, 147)	Week 6 (n= 104, 117, 125)	Endpoint (n= 151, 150, 153)
120-160mg Ziprasidone	-11.02	-14.59	-12.25
40-80 mg Ziprasidone	-12.16	-15.08	-13.36
Placebo	-12.25	-13.74	-12.78

Intervention	participants (Number)
	Week 1; Yes	Week 1; No	Week 2; Yes	Week 2; No	Week 3; Yes	Week 3; No	Week 4; Yes	Week 4; No	Week 5; Yes	Week 5; No	Week 6; Yes	Week 6; No	Endpoint; Yes	Endpoint; No
120-160mg Ziprasidone	18	143	48	87	56	64	55	51	65	34	58	37	73	93
40-80 mg Ziprasidone	27	126	41	101	61	70	65	61	66	49	63	44	72	86
Placebo	25	134	44	102	55	83	66	65	66	57	61	54	73	89

Intervention	Participants (Number)
	Week 1: Yes	Week 1: No	Week 2 : Yes	Week 2: No	Week 3: Yes	Week 3: No	Week 4: Yes	Week 4: No	Week 5: Yes	Week 5: No	Week 6: Yes	Week 6: No	Endpoint: Yes	Endpoint: No
120-160mg Ziprasidone	19	142	51	84	57	63	56	50	67	32	58	37	76	90
40-80 mg Ziprasidone	32	121	50	92	67	64	70	56	74	41	69	38	83	75
Placebo	26	133	51	95	60	78	68	63	71	52	67	48	80	82

Intervention	participants (Number)
	Baseline (n=43): normal, not ill at all	Baseline (n=43): borderline	Baseline (n=43): mildly ill	Baseline (n=43): moderately ill	Baseline (n=43): markedly ill	3 months (n=35): normal, not ill at all	3 months (n=35): borderline	3 months (n=35): mildly ill	3 months (n=35): moderately ill	6 months (n=34): normal, not ill at all	6 months (n=34): borderline	6 months (n=34): mildly ill	6 months (n=34): moderately ill	1 year (n=27): normal, not ill at all	1 year (n=27): borderline	1 year (n=27): mildly ill	1 year (n=27): moderately ill	3 years (n=10): normal, not ill at all	3 years (n=10): borderline	3 years (n=10): mildly ill	3 years (n=10): moderately ill	5 years (n=7): normal, not ill at all	5 years (n=7): borderline	5 years (n=7): mildly ill	End of Study [LOCF] (n=43): normal, not ill at all	End of Study [LOCF] (n=43): borderline	End of Study [LOCF] (n=43): mildly ill	End of Study [LOCF] (n=43): moderately ill	End of Study [LOCF] (n=43):markedly ill	End of Study [LOCF] (n=43): severely ill
Ziprasidone	4	20	14	4	1	6	13	10	6	8	10	11	5	6	10	9	2	1	5	2	2	1	4	2	4	9	9	10	8	3

Intervention	participants (Number)
	Baseline (n=43): very much improved	Baseline (n=43): much improved	3 months (n=35): very much improved	3 months (n=35): much improved	3 months (n=35): minimally improved	3 months (n=35): no change	6 months (n=34): very much improved	6 months (n=34): much improved	6 months (n=34): minimally improved	6 months (n=34): no change	6 months (n=34): minimally worsened	1 year (n=27): very much improved	1 year (n=27): much improved	1 year (n=27): minimally improved	1 year (n=27): no change	3 years (n=10): very much improved	3 years (n=10): much improved	3 years (n=10): no change	3 years (n=10): minimally worsened	5 years (n=7): very much improved	5 years (n=7): much improved	5 years (n=7): minimally improved	End of Study [LOCF] (n=43): very much improved	End of Study [LOCF] (n=43): much improved	End of Study [LOCF] (n=43): minimally improved	End of Study [LOCF] (n=43): no change	End of Study [LOCF] (n=43): minimally worsened	End of Study [LOCF] (n=43): much worsened
Ziprasidone	13	30	10	20	2	3	11	18	2	2	1	7	16	1	3	2	5	2	1	2	4	1	5	17	5	6	4	6

Intervention	participants (Number)
	Baseline (n=43): much better	Baseline (n=43): slightly better	Baseline (n=43): about the same	End of study (n=28): much better	End of study (n=28): slightly better	End of study (n=28): about the same	End of study (n=28): slightly worse	End of study (n=28): much worse
Ziprasidone	28	13	2	4	8	8	3	5